

6 Latin American Consensus on the Treatment of Head and Neck Cancer

Leandro Luongo Matos, MD, PhD^{1,2} ; Luiz Paulo Kowalski, MD, PhD³ ; Aline Lauda Freitas Chaves, MD, MSc⁴ ; Thiago Bueno de Oliveira, MD, PhD⁵ ; Gustavo Nader Marta, MD, PhD⁶ ; Maria Paula Curado, MD, PhD⁷ ; Gilberto de Castro Junior, MD, PhD⁸ ; Terence P. Farias, MD, MSc, PhD⁹ ; Gustavo Sarria Bardales, MD¹⁰ ; Mario Avila Cabrera, MD¹¹; Renato de Castro Capuzzo, MD, MSc¹² ; Genival Barbosa de Carvalho, MD, PhD⁷ ; Claudio Roberto Cernea, MD, PhD¹³ ; Rogério Aparecido Dedivitis, MD, PhD¹⁴ ; Fernando Luiz Dias, MD, PhD¹⁵ ; Andrés Munyo Estefan, MD¹⁶ ; Agustin Horacio Falco, MD¹⁷ ; Gustavo Alberto Ferraris, MD, PhD¹⁸ ; Alejandro Gonzalez-Motta, MD¹⁹ ; Andre Guimarães Gouveia, MD, MBA²⁰ ; Alexandre Arthur Jacinto, MD, PhD¹² ; Marco Aurelio Vamondes Kulcsar, MD, PhD²¹ ; Ana Kober Leite, MD, PhD²¹ ; Renan Bezerra Lira, MD, PhD²² ; Milena Perez Mak, MD, PhD²³ ; Pedro De Marchi, MD, PhD²⁴ ; Evandro Sobroza de Mello, MD, PhD²⁵ ; Fátima Cristina Mendes de Matos, MD, PhD²⁶ ; Pablo H. Montero, MD²⁷ ; Eduardo Dias de Moraes, MD²⁸ ; Fabio Ynoe de Moraes, MD, PhD²⁹ ; Diego Chaves Rezende Moraes, MD, MSc³⁰ ; Fernando Miguel Poenitz, MD³¹; Adela Poitevin, MD³² ; Hernán Ortiz Riveros, MD³³ ; Álvaro Sanabria, MD, MSc, PhD³⁴ ; Miguel Ticona-Castro, MD³⁵ ; José Guilherme Vartanian, MD, PhD³⁶ ; Gustavo Viani, MD, PhD³⁷ ; Eugenio F. Vines, MD³⁸ ; William Nassib William Junior, MD³⁹ ; David Conway, BDS, MPH, PhD⁴⁰ ; Shama Virani, PhD⁴¹ ; Paul Brennan, PhD⁴¹ ; and HEADSpAcE Consortium

DOI <https://doi.org/10.1200/GO.23.00343>

ABSTRACT

Head and neck squamous cell carcinoma (HNSCC) is well known as a serious health problem worldwide, especially in low-income countries or those with limited resources, such as most countries in Latin America. International guidelines cannot always be applied to a population from a large region with specific conditions. This study established a Latin American guideline for care of patients with head and neck cancer and presented evidence of HNSCC management considering availability and oncologic benefit. A panel composed of 41 head and neck cancer experts systematically worked according to a modified Delphi process on (1) document compilation of evidence-based answers to different questions contextualized by resource availability and oncologic benefit regarding Latin America (region of limited resources and/or without access to all necessary health care system infrastructure), (2) revision of the answers and the classification of levels of evidence and degrees of recommendations of all recommendations, (3) validation of the consensus through two rounds of online surveys, and (4) manuscript composition. The consensus consists of 12 sections: Head and neck cancer staging, Histopathologic evaluation of head and neck cancer, Head and neck surgery—oral cavity, Clinical oncology—oral cavity, Head and neck surgery—oropharynx, Clinical oncology—oropharynx, Head and neck surgery—larynx, Head and neck surgery—larynx/hypopharynx, Clinical oncology—larynx/hypopharynx, Clinical oncology—recurrent and metastatic head and neck cancer, Head and neck surgery—reconstruction and rehabilitation, and Radiation therapy. The present consensus established 48 recommendations on HNSCC patient care considering the availability of resources and focusing on oncologic benefit. These recommendations could also be used to formulate strategies in other regions like Latin America countries.

ACCOMPANYING CONTENT

 [Data Supplement](#)

Accepted February 7, 2024

Published April 11, 2024

JCO Global Oncol 10:e2300343

© 2024 by American Society of
Clinical Oncology

Licensed under the Creative
Commons Attribution 4.0 License

INTRODUCTION

Head and neck cancer is a global health problem. Squamous cell carcinoma (SCC) is the main histologic type and accounts for more than 90% of cases, and smoking, alcohol abuse, and human papillomavirus (HPV) infection remain the most relevant risk factors.^{1,2} The oral cavity, pharynx, and larynx are the most prevalent subsites of the disease with high incidences worldwide.³

The problem is even worse in lesser developed regions where 65% of all patients with head and neck squamous cell

carcinoma (HNSCC) and 75% of the deaths caused by the disease occur in the world.⁴ Access to specialized health care facilities, early diagnosis, treatment, or even best supportive care is challenging in countries with scarce resources, such as most Latin America countries.⁵ Multidisciplinary teams often have considerable structural problems and must treat patients under nonstandard conditions. The adaptation of published guidelines, which are mainly from developed countries, to real-world reality is challenging but extremely necessary.⁶

On the basis of this scenario, the aim of the present study was to establish Latin American guidelines for

the care of patients with HNSCC considering availability of resources and focusing on oncologic benefit to provide a guide for other countries worldwide facing the same reality. Because of the inequity that is unfortunately a reality in Latin America, the panel also demonstrated the best level of evidence in some questions and included recommendations sometimes on gold-standard approaches to provide a definitive guide for specialists in the field in the region and in other similar realities worldwide.

DESIGN

Panel

The panel was composed of 41 head and neck cancer experts in different fields related to head and neck cancer treatment, chosen as some of the different national leaders on the field. All of them were coauthors of this study. The interaction between the panel was performed exclusively online through e-mail correspondence during all the different stages of the guidelines' conduction.

Guidelines

In a modified Delphi process,⁷ two invited specialists, part of the 41-panel expert, were assigned to answer a specific group of questions on the basis of the relevant sections of the consensus and individual expertise. These authors were asked to write the answers to the questions, evaluating the standard of care and establishing, wherever possible, the minimum requirements necessary for adequate patient management, considering the availability of resources and oncologic benefit in the context of Latin America (region of limited resources and/or without access to the necessary health care system infrastructure). The answers should be contextualized with the main international guidelines, considering the availability of resources and oncologic benefits as in Latin America.

First Stage: Document Writing, Search Strategy, Reference Selection Criteria, and Evidence Classification

A short answer that cited appropriate references and explained the main results of the selected studies and the rationale for their selection was requested for each question.

The two specialists designated to answer each specific book of questions were free to select the relevant references in the literature, without any reference selection, criteria, or search strategy. To ensure an evidence-based consensus, each reference included in the support of the answer to each specific question was classified according to the level of evidence and degree of recommendation, as described in Table 1.

After the description of the literature, the authors ended their essays with a summary paragraph objectively answering each question.

Second Stage: Review from the Executive Board

The answers to all consensus questions were reviewed by the entire executive board (L.L.M., L.P.K., A.L.F.C., T.B.d.O., G.N.M., and M.P.C. coauthors). During this analysis period, alternative answers were forwarded to the coauthors, and requests for reviews were also forwarded to them when necessary. The level of evidence and degree of recommendations were also determined by a health research methodology expert (L.L.M. author) at this stage, and the list of references used to answer each question was also reviewed to just stratify those with high-quality evidence, wherever possible.

Third Stage: Consensus (validation)

The executive board produced an online survey recorded using Research Electronic Data Capture software (REDCap 11.2.5—2022 Vanderbilt University). The survey was composed of 116 questions divided into the 12 sections of

TABLE 1. Classification System for the Level of Evidence and Degree of Recommendation Applied to All References Selected for the Study

Level of Evidence	Study Design	Degree of Recommendation	Description
1	Systematic review with a meta-analysis or randomized study with adequate sample (strait 95% CI)	A (very strong)	The evidence is reliable, the uncertainties are small, and the research can be used to guide clinical practice
2	Randomized study with uncalculated or inadequate sample (large 95% CI)	B (strong)	The existing evidence is reliable and can be used to guide clinical practice in most cases, but there are some uncertainties to consider
3	Prospective, nonrandomized study or randomized study with a nonstandard comparator	C (moderate)	The existing evidence provides some support for the recommendations, but their application may be debatable
4	Retrospective study	D (weak)	The existing evidence is weak, or the uncertainties are too great. Recommendations should be applied carefully

NOTE. The level of evidence and degree of recommendation are different and independent parameters.

this study. The survey was then sent to all coauthors, whose responses were mandatory. The objective answers to all questions were voted on by the entire group with a binary system of agreement (“I agree” or “I do not agree”). It was also possible to allow the responders to choose not to answer a question if it was not in their area of expertise. In cases of disagreement with any statement, the coauthors were asked to justify their answers to facilitate the review of each point. At this point, all coauthors could suggest missing references to improve the evidence-based quality of the consensus.

A consensus was considered when agreement about the survey responses was obtained from more than two thirds of the coauthors. In this situation, there was no need for further discussion.

There was a lack of consensus regarding seven questions. The executive board reviewed the sentences and the recommendations, and another survey was built and sent to all the coauthors for a new round of vote, displaying all received inputs in an anonymized manner that allowed every panel member to view each comment from their peers.⁷ Again, it was considered a consensus when agreement regarding the answers of the new vote round was reached by more than two thirds of the coauthors. In cases of persistent disagreement, the answer to the question was published with a notation that there was no consensus reached among the coauthors regarding that statement.

The two surveys and agreement rates are demonstrated in the Supplement.

Fourth Stage: Approval of the Manuscript

The drafting of the consensus was written by the executive board and based on the document sent by all coauthors and agreed upon by the votes of the surveys. The final manuscript was approved by all participants.

CONSENSUS

This study was divided into 12 sections regarding the management and treatment of patients with HNSCC, according to 48 different questions, as described in Table 2. To facilitate understanding of the recommendations, the different sites were grouped as head and neck cancer when the management and treatment were similar regardless of the specific site; otherwise, specific recommendations were determined for oral, oropharyngeal, laryngeal, or hypopharyngeal SCC, but not with substratification into subsites, where there are main controversies.

All data regarding the literature review that sustains each recommendation are available in the Supplement.

TABLE 2. Consensus Content and Corresponding Recommendations

Content	Recommendation No.
SECTION 1. Head and Neck Cancer Staging	
1.1. Is a clinical examination alone or panoramic radiography acceptable for the evaluation of a tumor next to the bone?	1
1.2. Is neck ultrasound sufficient for the evaluation of nonpalpable lymph nodes?	2
1.3. For locoregional staging, when is a CT scan or MRI indicated?	3
1.4. When should chest radiography, tomography, or PET-CT be performed for distant disease evaluation?	4
1.5. When should a second primary tumor be screened for? How?	5
SECTION 2. Histopathological evaluation—Head and Neck cancer	
2.1. Should frozen sections be mandatory for negative margin evaluation? Should the margins be evaluated on a tumor specimen or on separate fragments?	6
2.2. What is the appropriate margin for the surgical treatment of tumors of the oral cavity, oropharynx, larynx, and hypopharynx?	7
2.3. When is p16 evaluation necessary? How should staging be performed if this exam is unavailable?	8
2.4. When should we consider close margins? Should close margins be considered positive margins?	9
SECTION 3. Head and Neck Surgery—Oral Cavity	
3.1. Can sentinel lymph node biopsy be considered the standard of care in the neck evaluation of stage I and II tumors? What should be the approach when this methodology is not available?	10
3.2. What is the recommended number of lymph nodes for a neck dissection specimen to consider the specimen representative?	11
3.3. When is radical neck dissection (modified, classic, or extended) the recommended option for treating a positive neck?	12
SECTION 4. Clinical Oncology—Oral Cavity	
4.1. What factors should be considered indications for adjuvant chemotherapy associated with radiation therapy, outside positive margins, and extracapsular spread?	13
4.2. Would you consider once a week cisplatin (40 mg/m ²) concurrent with adjuvant radiation instead of the high-dose regimen (100 mg/m ²) once every 3 weeks?	14
4.3. Is there any indication for induction (neoadjuvant) chemotherapy in resectable oral cavity tumors? For unresectable or “borderline” resectable oral cavity tumors, would you consider induction (neoadjuvant) chemotherapy followed by surgery in any scenario? Would you consider this followed by chemotherapy plus radiation?	15
4.4. For patients with locally advanced unresectable disease who are unfit for cisplatin, would you consider once a week concurrent (concomitant) cetuximab?	16

(continued on following page)

TABLE 2. Consensus Content and Corresponding Recommendations (continued)

Content	Recommendation No.
SECTION 5. Head and Neck Surgery—Oropharynx	
5.1. When should transoral approaches (robot, laser, or conventional transoral) be used?	17
5.2. When should surgery be indicated as the initial treatment for T3 or T4 tumors?	18
5.3. Should neck dissection be performed at the same time as transoral surgery or at another time?	19
5.4. What neck levels should be included in negative neck dissection?	20
5.5. When does neck dissection need to be bilateral in a negative neck?	21
SECTION 6. Clinical Oncology—Oropharynx	
6.1. For surgically treated HPV-positive patients with locally advanced disease (T3/T4 and/or node-positive disease), would you consider de-escalating adjuvant treatment (omitting radiation, reducing the dose of radiation, or omitting concurrent chemotherapy for high-risk patients) in any subgroup of patients?	22
6.2. For patients with locally advanced HPV-positive disease who are candidates for a nonsurgical approach, would you consider de-escalation strategies in any subgroup of patients?	23
6.3. Would you consider trimodality treatment (surgery followed by chemoradiation) in any subgroup of patients with oropharyngeal cancer?	24
6.4. For locally advanced HPV-positive or HPV-negative disease, would you consider induction (neoadjuvant) chemotherapy before chemoradiation or surgery in any subgroup of patients?	25
SECTION 7. Head and Neck Surgery—Larynx	
7.1. When should surgical treatment be performed for T1 and T2 tumors?	26
7.2. When indicated, what is the preferred surgical treatment for T1b tumors?	27
7.3. When is endoscopic resection or open partial laryngectomy indicated?	28
SECTION 8. Head and Neck Surgery—Larynx/Hypopharynx	
8.1. When are age and respiratory condition contraindications for partial laryngectomies?	29
8.2. What are the absolute indications for total laryngectomy as the primary treatment for laryngeal or hypopharyngeal tumors?	30
8.3. What cervical levels should be included in negative neck dissection for supraglottic tumors?	31
8.4. When should thyroidectomy and central compartment dissection be indicated in laryngeal and hypopharyngeal tumors?	32
SECTION 9. Clinical Oncology—Larynx/Hypopharynx	
9.1. Would you consider concurrent chemoradiation as definitive treatment for high-risk T2 hypopharyngeal carcinoma?	33

(continued in next column)

TABLE 2. Consensus Content and Corresponding Recommendations (continued)

Content	Recommendation No.
9.2. Is once a week cisplatin concurrent with radiation therapy a good strategy for organ preservation in T3 laryngeal/hypopharyngeal carcinoma?	34
9.3. Would you consider a nonsurgical organ preservation strategy for any subgroup of patients with T4 laryngeal and hypopharyngeal carcinoma?	35
9.4. Would you consider induction chemotherapy followed by radiation therapy or concurrent radiation plus chemotherapy as an organ preservation strategy for locally advanced laryngeal/hypopharyngeal carcinoma?	36
9.5. Would you consider cetuximab plus radiation therapy as an organ preservation strategy for patients with laryngeal and hypopharyngeal carcinoma who are unfit for cisplatin?	37
SECTION 10. Clinical Oncology—Recurrent and metastatic Head and Neck Cancer	
10.1. What is the preferred regimen for first-line treatment for patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 recurrent and metastatic HNSCC who are not amenable for local therapies according to PD-L1 combined positive score (CPS) expression (PD-L1 – negative, 1-19, or higher than 20)? What is the second-line treatment recommended after progression in these situations?	38
10.2. For patients with an ECOG PS of 2 and HNSCC, what is the recommended systemic first-line treatment? Should PD-L1 CPS expression be considered when choosing the regimen?	39
SECTION 11. Head and Neck Surgery—Reconstruction and Rehabilitation	
11.1. When is free-flap reconstruction indispensable in reconstruction?	40
11.2. When should pharyngeal reconstruction be indicated in laryngeal and hypopharyngeal tumors?	41
11.3. What are the indications for the different phonatory rehabilitation methods?	42
SECTION 12. Radiation Therapy	
12.1. Technique. Is IMRT the most appropriate technique for the treatment of patients with HNSCC? Is the 3D conformal technique (3DCRT) an acceptable option for the treatment of patients with HNSCC? Is 3DCRT a well-suited technique for the treatment of patients with early-stage glottic laryngeal cancer? Is conventional two-dimensional radiation therapy (2DRT) an acceptable technique option for the treatment of patients with HNSCC?	43
12.2. Simulation. Should CT simulation be performed using a slice thickness of 3 mm or less? Is intravenous contrast needed for target delineation, mostly with respect to identification of the cervical lymph nodes?	44
12.3. Target volumes and treatment deintensification. Should target volumes and organs at risk be defined based on international guidelines (eg, ASTRO and/or	45

(continued on following page)

TABLE 2. Consensus Content and Corresponding Recommendations (continued)

Content	Recommendation No.
ESTRO)? Can treatment deintensification reducing target volumes and/or total radiation dose for HPV-related oropharyngeal cancer be considered the standard of care? Should target volumes and organs at risk be peer reviewed by an additional radiation oncology staff?	
12.4. Treatment dose and treatment planning. Could moderately hypofractionated radiation therapy (eg, 44-48 Gy/20 fractions) be considered a treatment option for patients with HNSCC in a curative setting? Should altered fractionation (ie, 6 fractions per week) be strongly considered in patients with locally advanced HNSCC in whom exclusive radiation therapy is indicated? Should altered fractionation (ie, 6 fractions per week) be strongly considered in patients with locally advanced HNSCC when concurrent chemotherapy and radiation therapy are indicated? For early-stage glottic laryngeal cancer, should moderately hypofractionated radiation therapy with 63 Gy in 28 fractions and 65.25 Gy in 29 fractions (2.25 Gy/fraction) for T1N0 and T2N0 tumors, respectively, be recommended? Regarding radiation therapy planning, should 95% of the planning target volume (PTV) for each dose level receive the prescription dose? Should the final plans be peer reviewed by an additional radiation oncology staff before final approval?	46
12.5. Image-Guided Radiation Therapy. Is it recommended to perform IGRT with a CB prior to a radiation session to ensure accuracy? Is it recommended to perform IGRT with planar imaging (2D) prior to a radiation session to ensure accuracy? Must IGRT (CB/2D imaging) be performed daily? Must IGRT (CB/2D imaging) be performed on the first 3 days of treatment and then once a week?	47
12.6 Time to initiate treatment and physician evaluation. Is it recommended to initiate radical radiation therapy within 6-8 weeks of diagnosis? Is it recommended to initiate postoperative radiation therapy within 6-8 weeks of surgery? Must the indications for postoperative radiation therapy be maintained even whether treatment starts 8 weeks postoperatively? During radiation therapy treatment, must the patient be evaluated by the physician at least once a week? Should discontinuation of or breaks in radiation therapy be avoided (unless it is clinically necessary)?	48

Abbreviations: ASTRO, American Society for Therapeutic Radiology and Oncology; 2DRT, two-dimensional radiation therapy; 3D, three-dimensional; CB, cone beam; CPS, combined positive score; CRT, conformal technique; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; ESTRO, European Society for Radiotherapy and Oncology; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IGRT, image-guided radiation therapy; IMRT, intensity modulated radiotherapy; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; PTV, planning target volume.

Section 1. Head and Neck Cancer Staging

The aim of this section is to establish the minimum pretreatment evaluation for clinical staging considering the standard of care. All recommendations regarding head and neck cancer staging are described in [Table 3](#).

Clinical examination, with or without panoramic radiography, may be sufficient for assessing cancer near bone in cases of large, clearly bone-compromising lesions, especially those requiring segmental mandibulectomy. However, its accuracy is limited. Ideally, sectional imaging methods like computed tomography (CT) scan or magnetic resonance imaging (MRI) should be used, particularly for patients with gingival or maxillofacial tumors lacking evident bone involvement. When bone involvement is uncertain, both CT scan and MRI are essential as they offer comparable accuracy in detecting mandibular invasion.⁸⁻¹¹

Neck ultrasound, on its own, is inadequate for a thorough assessment of nonpalpable lymph nodes in head and neck cancer staging. Nevertheless, it could serve as the sole imaging option in low-resource settings when elective neck dissection (END) is programmed although it relies heavily on the operator's skill. Its accuracy increases when combined with a fine-needle aspiration biopsy, but its diagnostic effectiveness remains comparable with that of a more convenient CT scan.^{12,13}

Given the greater availability and lower cost of CT scans compared with MRI in many centers, it is advisable to opt for CT scans rather than MRI when dealing with resource limitations for locoregional staging of head and neck cancer. In addition, recent evidence does not suggest a significant difference in accuracy between the two methods.¹⁴⁻¹⁶

At a minimum, chest radiography should be conducted for all patients to assess distant disease in head and neck cancer staging. Nevertheless, for patients with advanced disease, particularly those with N2 or N3 neck disease, a CT scan is recommended. Positron emission tomography-computed tomography provides the highest accuracy in detecting distant metastasis and should be considered especially for high-risk patients, such as those with HPV-related carcinomas, as these cancers may metastasize to atypical sites.¹⁷⁻²⁵

Patients with tobacco-related head and neck cancer should undergo a thorough assessment for additional primary malignancies in the upper aerodigestive tract. This assessment should encompass a comprehensive locoregional examination, including nasopharyngolaryngoscopy, upper GI endoscopy, and chest imaging.^{22,26-30}

TABLE 3. Recommendations Regarding Head Neck Cancer Staging Histopathologic Evaluation

Recommendation	Level of Evidence	Degree of Recommendation
SECTION 1. Head and Neck Cancer Staging		
Recommendation 1		
Clinical examination, with or without a panoramic radiography, could be sufficient to evaluate a cancer near the bone in cases of bulky lesions clearly compromising the bone, especially in cases with indications for segmental mandibulectomy, but with inferior accuracy	4	C
In an ideal scenario, a sectional imaging method should be employed, such as a CT scan or MRI, mainly in patients with gingival tumors or tumors located close to the mandible or maxilla without gross bone involvement	1	C
In cases of questionable bone involvement, a CT scan and/or MRI is required, and both exams have similar accuracy to detect mandibular invasion	1	B
Recommendation 2		
Neck ultrasound alone is insufficient to properly evaluate nonpalpable lymph nodes in head and neck cancer staging. However, it could be the unique imaging modality if an elective neck dissection is planned in low-resource settings, but it is highly operator-dependent. The accuracy of the method is improved when performed with a fine-needle aspiration biopsy, but the diagnostic power is similar to a CT scan, which is much easier to perform	3	C
Recommendation 3		
As CT scan is a method that is much more readily available in several centers than MRI, and it has a lower cost than MRI, therefore, in a scenario of limited resources, CT should be employed instead of MRI for locoregional staging of head and neck cancer. Furthermore, the most recent evidence does not support accuracy improvement from one method over another	1	C
Recommendation 4		
At minimum, chest radiography should be performed for all patients to evaluate distant disease in head and neck cancer staging; however, a CT scan should be performed in patients with advanced disease, mainly those with N2 or N3 neck disease	4	C
PET-CT has the best accuracy in the detection of distant metastasis and should be considered in high-risk patients, especially for HPV-related carcinomas, due to the risk of distant metastasis at unusual sites	2	C
Recommendation 5		
All patients with tobacco-associated head and neck cancer should be carefully evaluated to exclude a synchronous and metachronous second primary malignancy of the upper aerodigestive tract. This evaluation should include a detailed locoregional examination combined with nasopharyngolaryngoscopy, upper gastrointestinal endoscopy, and chest imaging	1	C
SECTION 2. Head and Neck Cancer—Histopathologic evaluation		
Recommendation 6		
Frozen section examination is an important tool to assure a complete and oncological tumor resection	1	D
Margin evaluation at the specimen level is the best strategy to decrease local recurrence, and it is a more accepted practice	3	C
Recommendation 7		
Margins >5 mm based on the surgical specimen can be considered negative for oral, oropharyngeal, supraglottic, and hypopharyngeal tumors. Exclusively for glottic tumors, margins >1 mm are considered negative	3	C
Recommendation 8		
Margins between 1 and 5 mm are classified as close and <1 mm as positive for oral, oropharyngeal, supraglottic, and hypopharyngeal tumors. Exclusively for glottic tumors, margins <1 mm are considered close margins for these cases	1	C
In general, close margins for HNSCC should not be considered positive margins based on the current evidence, and their correct prognosis and management should be better determined	1	D
Recommendation 9		
All patients with oropharyngeal SCC should have an HPV status evaluation, and p16 immunostaining is the easiest way to first perform this evaluation. Once, until now, there is no change at treatment, and if unavailable, HPV evaluation should not delay treatment initiation	2	B

Abbreviations: CT, computed tomography; HPV, human papillomavirus; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; SCC, squamous cell carcinoma.

TABLE 4. Recommendations Regarding the Management of Patients With Oral Cavity or Oropharynx Squamous Cell Carcinoma

Recommendation	Level of Evidence	Degree of Recommendation
SECTION 3. Head and Neck Surgery—Oral Cavity		
Recommendation 10		
SLNB should be employed in patients with stages I and II oral SCC when all the resources, such as appropriate preoperative imaging, specialized head and neck cancer radiologist, nuclear medicine services, radiolabeled markers, an adequate pathologist, and immunohistochemistry techniques, are available. Otherwise, SND should continue to be the standard of care for those patients. Active surveillance of the neck should not be recommended	1	A
Recommendation 11		
A LNY higher than 18 is a quality metric in head and neck surgery, specifically in patients undergoing elective neck dissection. The surgical technique can significantly impact the LNY, but also it is possible to improve this evaluation with the application of more rigorous specimen processing by the pathology team. Subsequently, this measure could yield more accurate nodal staging and ultimately drive more appropriate use of adjuvant therapy	4	B
Recommendation 12		
SND is an acceptable alternative to CND or RND in patients with stage T1 or T2 and cN1 oral cavity SCC and for very selected cN2 cases, sited at levels I or II. However, RND and CND are still the standard of care in patients with oral cancer with advanced T-stage disease (T3 or T4) or cN2 and cN3 disease, which require primary surgical treatment	1	B
SECTION 4. Clinical Oncology—Oral Cavity		
Recommendation 13		
There is a strong recommendation for adjuvant concurrent chemoradiation over adjuvant radiation therapy alone primarily for patients with positive surgical margins and/or metastatic lymph nodes with ENE.	1	A
The presence of more than two positive lymph nodes is also an indication for postoperative chemoradiation	4	B
The presence of perineural invasion, perivascular invasion, involvement of multiple lymph nodes, and lymph node involvement at low cervical levels (IV and V) could, in highly selected cases and after multidisciplinary discussion, be considered for concurrent chemoradiation	1	C
Recommendation 14		
Adjuvant (postoperative) concurrent chemoradiation with once a week cisplatin (40 mg/m ²) can be used instead of the high-dose regimen (100 mg/m ²) once every 3 weeks	1	A
Recommendation 15		
Induction (neoadjuvant) chemotherapy may be considered in unresectable or borderline resectable oral cavity tumors in highly selected cases with multidisciplinary input	4	C
Recommendation 16		
There is no evidence to prescribe cetuximab concurrent with radiation therapy in patients with oral cavity unsuitable to receive cisplatin	4	D
For these patients, radiation therapy concurrent with docetaxel is an option	1	B
SECTION 5. Head and Neck Surgery—Oropharynx		
Recommendation 17		
Transoral approaches (TORS or TLM) with or without neck dissection and adjuvant radiotherapy or chemoradiation should be used in T1-2 N0-2 oropharyngeal SCC and could be used in selected cases of T3 N0-2 oropharyngeal SCC, regardless of HPV status. Conventional transoral surgery should be used in cases without availability of robotic tools or when an expert transoral endoscopic surgeon is unavailable. Conventional surgical and nonsurgical treatment provides comparable oncologic results	1	C
Recommendation 18		
For selected cases of T3 oropharyngeal SCC, TORS or TLM may be indicated, depending upon the need for reconstruction of the soft palate. Conventional open surgery may be indicated for patients with T3-4a oropharyngeal SCC who are not amenable to chemoradiation with high-dose cisplatin but who are fit for a major surgical procedure with reconstruction and adjuvant treatment, with a reasonable expectation of favorable functional results	3	C
Recommendation 19		
In transoral surgery (TORS or TLM), if the primary oropharyngeal tumor does not require a radical tonsillectomy and the submandibular gland can be preserved during neck dissection, a concurrent approach (transoral surgery with neck dissection) is preferred. On the other hand, if radical tonsillectomy is planned or if the submandibular gland must be removed, staged procedures 10-14 days apart should be advocated, starting with neck dissection with ligation of the branches of the external carotid artery	4	C

(continued on following page)

TABLE 4. Recommendations Regarding the Management of Patients With Oral Cavity or Oropharynx Squamous Cell Carcinoma (continued)

Recommendation	Level of Evidence	Degree of Recommendation
Recommendation 20		
Patients with neck-negative oropharyngeal SCC primarily treated with surgery should receive, at least, dissections of levels II-IV. An absolute consensus has not yet been reached, but level I can be omitted in select cases. HPV or p16 status does not require modification of this indication yet.	4	C
Recommendation 21		
Regardless of HPV status, bilateral elective neck dissection is recommended for all cases of oropharyngeal SCC that extend to or approach the midline. For lateralized tumors that involve the tongue base, soft palate, and posterior pharyngeal wall, elective bilateral neck dissection should be considered due to contralateral lymphatic drainage	4	C
SECTION 6. Clinical Oncology—Oropharynx		
Recommendation 22		
Despite the good prognosis of patients with HPV-positive tumors, patients with locally advanced oropharyngeal treated with surgery should receive adjuvant treatment, regardless of HPV status	1	A
Patients with low-risk HPV-positive oropharyngeal SCC, stage T1/T2 disease with free margins, no invasion, and up to one positive lymph node measuring <3 cm and without ENE can be considered for observation after surgery	1	C
There was no consensus if patients with intermediate-risk HPV-positive oropharyngeal SCC (close margins, <1 mm ENE, or 2-4 metastatic nodes, perineural invasion, or lymphovascular invasion) can be considered for treatment de-escalation—mainly with a reduced dose of radiation and omission of chemotherapy	1	C
Recommendation 23		
In a definitive setting, patients with HPV-positive oropharyngeal SCC should be treated the same as those patients with HPV-negative tumors	1	A
Recommendation 24		
Trimodality treatment should be avoided in locally advanced oropharyngeal cancer	1	A
Recommendation 25		
Cisplatin-based concurrent chemoradiation is the standard-of-care nonsurgical treatment for locally advanced oropharyngeal carcinoma	1	A
Induction chemotherapy can be considered in patients with high-volume disease, those with a high risk of distant metastasis, symptomatic patients in need of a rapid response, and those in whom delayed initiation of radiotherapy is expected	1	B

Abbreviations: CND, comprehensive neck dissection; ENE, extranodal extension; HPV, human papillomavirus; LNY, lymph node yield; RND, radical neck dissection; SCC, squamous cell carcinoma; SLNB, sentinel lymph node biopsy; SND, selective neck dissection; TLM, transoral laser microsurgery; TORS, transoral robotic surgery.

Section 2. Head and Neck Cancer—Histopathologic Evaluation

The aim of this section is to present the evidence of the assessment of intraoperative margins and histopathologic evaluation of head and neck cancer considering availability of resources and oncologic benefit, and the recommendations are presented in [Table 3](#).

Frozen section examination plays a crucial role in ensuring an oncologic tumor resection. Evaluating margins at the specimen is considered the most effective strategy for reducing the risk of local recurrence, and it has gained wider acceptance in current practice.³¹⁻⁵⁴

Margins >5 mm can be classified as negative for oral, oropharyngeal, supraglottic, and hypopharyngeal tumors, and >1 mm for glottic tumors.^{46,53,55-60}

Margins between 1 and 5 mm are categorized as close margins, whereas those measuring <1 mm are classified

as positive margins for oral, oropharyngeal, supraglottic, and hypopharyngeal tumors and for glottic tumors, and margins <1 mm are considered close margins. Generally, close margins for HNSCC should not be considered as positive margins on the basis of current evidence. The prognosis and appropriate management of close margins in HNSCC cases should be more precisely determined.^{42,56,57,59,61,62}

All patients diagnosed with oropharyngeal SCC should undergo an HPV status evaluation, and p16 immunostaining is a convenient initial method for this assessment. If p16 immunostaining is unavailable, the evaluation of HPV status should not cause any delay in the initiation of treatment.⁶³⁻⁶⁵

Section 3. Head and Neck Surgery—Oral Cavity

The aim of this section is to present the evidence of the different neck approaches for oral cavity SCC, considering their availability and oncologic benefit, as described in [Table 4](#).

Sentinel lymph node biopsy should be used in patients with stage I and II oral SCC when all the resources, such as appropriate preoperative imaging, a specialized head and neck cancer radiologist, nuclear medicine services, radiolabeled markers, an adequate pathologist, and immunohistochemistry techniques, are available. Otherwise, selective neck dissection (SND) should continue to be the standard of care for those patients. Active surveillance of the neck should not be recommended.⁶⁶⁻⁷⁴

A lymph node yield (LNY) higher than 18 is a quality metric in head and neck surgery, specifically in patients undergoing END. Not only the surgical technique can significantly affect the LNY, but also it is possible to improve this evaluation with the application of more rigorous specimen processing by the pathology team. Subsequently, this measure could yield more accurate nodal staging and ultimately drive more appropriate use of adjuvant therapy.⁷⁵⁻⁸⁰

SND is an acceptable alternative to comprehensive neck dissection (CND) or radical neck dissection (RND) in patients with stage T1 or T2 and cN1 oral cavity SCC and for very selected cN2 cases, sited at levels I or II. However, RND and CND are still the standard of care in patients with oral cancer with advanced T-stage disease (T3 or T4) or cN2 and cN3 disease, which require primary surgical treatment.^{62,81-91}

Section 4. Clinical Oncology—Oral Cavity

The aim of this section is to present the evidence for systemic treatment of locally advanced oral cavity SCC, summarized in Table 4.

A robust recommendation favors adjuvant concurrent chemoradiation over adjuvant radiation therapy alone, particularly for patients with positive surgical margins and/or metastatic lymph nodes showing extranodal extension (ENE). In select cases, chemoradiation may also be given for patients with perineural invasion, perivascular invasion, involvement of multiple lymph nodes, and lymph node involvement at lower cervical levels (IV and V).⁹²⁻⁹⁹

Adjuvant (postoperative) concurrent chemoradiation with once a week cisplatin (40 mg/m²) can be used instead of the high-dose regimen (100 mg/m²) once every 3 weeks.¹⁰⁰

Induction (neoadjuvant) chemotherapy may be considered in unresectable or borderline resectable oral cavity tumors in highly selected cases with multidisciplinary input.¹⁰¹⁻¹⁰⁴

There is no evidence to recommend the use of cetuximab concurrently with radiation therapy for patients with oral cavity SCC who are not suitable for cisplatin. In such cases, an alternative option is concurrent radiation therapy with docetaxel.¹⁰⁵⁻¹⁰⁸

Section 5. Head and Neck Surgery—Oropharynx

The aim of this section is to present the evidence of different primary tumor and neck approaches in oropharyngeal SCC, considering their availability and oncologic benefit, as shown in Table 4.

Transoral approaches, such as transoral robotic surgery (TORS) or transoral laser microsurgery (TLM), are recommended for T1-2 N0-2 oropharyngeal SCC. In selected cases, they can also be considered for T3 N0-2 tumors, independent of HPV status. In cases where robotic tools are unavailable or when there is a lack of expertise in transoral endoscopic surgery, conventional transoral surgery should be used. Conventional surgical and nonsurgical treatments yield similar oncologic outcomes.¹⁰⁹⁻¹³⁰

In specific cases of T3 tumors, the choice between TORS or TLM may be appropriate, depending on the necessity for soft palate reconstruction. For patients with T3-4a tumors who are not suitable for high-dose cisplatin-based chemoradiation but are fit for a major surgical procedure with reconstruction and subsequent adjuvant treatment, conventional open surgery may be recommended. This approach should be considered when there is a reasonable expectation of achieving favorable functional outcomes.^{109,115-117,119,121,124,126,128,130-134}

In transoral surgery (TORS or TLM) when the primary tumor does not need a radical tonsillectomy and the preservation of the submandibular gland is feasible during neck dissection, a concurrent approach is the preferred strategy. Conversely, if radical tonsillectomy is part of the plan or if removal of the submandibular gland is required, a staged approach involving two procedures spaced 10-14 days apart is recommended. The sequence typically starts with neck dissection, which includes ligation of the branches of the external carotid artery.¹³⁵⁻¹⁴⁰

Patients with neck-negative oropharyngeal SCC who are primarily treated with surgery should undergo dissections of, at least, levels II-IV. While there is not an absolute consensus, in some selected cases, the omission of level I dissection may be considered. HPV or p16 status does not currently necessitate a modification of this guideline.^{126,141-152}

Irrespective of HPV status, bilateral END is advised for oropharyngeal SCC cases approaching the midline. In lateralized tumors affecting the tongue base, soft palate, and posterior pharyngeal wall, elective bilateral neck dissection should be considered because of contralateral lymphatic drainage.^{126,141-143,148,153-155}

Section 6. Clinical Oncology—Oropharynx

The aim of this section is to present the evidence for systemic treatment in locally advanced HPV-positive and HPV-negative oropharyngeal carcinoma and for de-escalation strategies in HPV-positive disease. The recommendations are presented in Table 4.

Despite the generally favorable prognosis of patients with HPV-positive tumors, patients with locally advanced oropharyngeal cancer treated surgically should still receive adjuvant treatment, regardless of their HPV status. However, for patients with low-risk HPV-positive oropharyngeal SCC (T1/T2 disease with clear margins, minimal invasion, and limited lymph node involvement without ENE), observation after surgery can be considered. In cases of intermediate-risk HPV-positive tumors (involving factors like close margins, <1 mm ENE, 2–4 metastatic nodes, perineural invasion, or lymphovascular invasion), there is no consensus on whether treatment de-escalation, particularly reducing radiation dosage and omitting chemotherapy, can be considered.^{111,156–158}

In a definitive setting, patients with HPV-positive oropharyngeal SCC should be treated the same as those patients with HPV-negative tumors.^{159–161}

Trimodality treatment (surgery followed by chemoradiation) should be avoided in locally advanced oropharyngeal cancer.^{162–167}

The standard-of-care nonsurgical treatment for locally advanced oropharyngeal SCC is cisplatin-based concurrent chemoradiation. However, in certain cases, induction chemotherapy may be considered. This includes patients with high-volume disease and a high risk of distant metastasis, symptomatic patients requiring a rapid response, and those expected to face a delay in starting radiotherapy.^{168–182}

Section 7. Head and Neck Surgery—Larynx

The aim of this section is to present the evidence for the different primary tumor approaches in laryngeal SCC, considering their availability and oncologic benefit, and is described in [Table 5](#).

Both surgery and radiotherapy are valid options for T1 and T2 laryngeal SCC with similar outcomes. Surgery, especially TLM, provides low local recurrence and supports larynx preservation, while radiotherapy can improve vocal outcomes. The choice between these treatments should involve a patient-centered discussion considering individual preferences and circumstances.^{183–189}

When surgical treatment is considered, the preferred surgical treatment for T1b laryngeal SCC is TLM. In patients with inadequate exposure, frontolateral vertical laryngectomy is an option.^{189–191}

Open partial laryngectomies are currently recommended for laryngeal tumors with limited transoral access and specific anterior commissure tumors with vertical extension and also for selected patients who need surgical salvage therapy.^{184,187,192,193}

Section 8. Head and Neck Surgery—Larynx/Hypopharynx

The aim of this section is to present the evidence of the different primary tumor and neck approaches in laryngeal and/or hypopharyngeal SCC, considering their availability and oncologic benefit. The recommendations are presented in [Table 5](#).

Elderly patients should receive curative treatment, considering their overall health and disease stage. Chronologic age alone should not determine treatment decisions, but it is essential to recognize that elderly patients often have more comorbidities and are at a higher risk of postoperative complications.^{194–205}

Nonsurgical treatments for laryngeal or hypopharyngeal SCC should be considered for patients who cannot undergo partial laryngectomy and those with stage T3 and low-volume stage T4a tumors that still have a preservable larynx but are candidates for total laryngectomy. Total laryngectomy is recommended for cases involving laryngeal dysfunction, extensive infiltrative tumors with cartilage invasion and extralaryngeal spread, or when nonsurgical organ preservation treatments have failed.^{206–227}

For stage T1 and T2 No supraglottic tumors of the ventricular bands or ventricles that do not approach the midline, it is advised to perform END on the ipsilateral side, encompassing at least levels IIA and III. For those in the epiglottis or aryepiglottic fold and those approaching the midline, it is recommended to opt for bilateral END, covering at least levels IIA and III. In cases of stage T3 and T4 No supraglottic tumors, bilateral END involving levels IIA, III, and IV is indicated. In addition, anterior compartment dissection and thyroidectomy are needed if there is extension into the paraglottic space.^{126,228–234}

Central compartment dissection (level VI) and thyroidectomy should be considered in the following cases of laryngeal and/or hypopharyngeal cancer: primary or subglottic extension advanced glottic SCC (T3–T4), especially if it involves the anterior commissure, cricoid cartilage, or subglottic extension; advanced supraglottic SCC (T3–T4), especially if it involves the ventricle/paraglottic space, involves anterior commissure, or has lymph node metastases in the lateral neck compartment; and hypopharyngeal SCC.^{235–248}

Section 9. Clinical Oncology—Larynx/Hypopharynx

The aim of this section is to establish candidate patients for nonsurgical organ preservation strategies and to present the evidence for systemic treatment in these scenarios including a discussion about patients living in a resource-constrained environment. All statements are summarized in [Table 5](#).

TABLE 5. Recommendations Regarding the Management of Patients With Larynx and/or Hypopharynx Squamous Cell Carcinoma and the Management of Recurrent or Metastatic Head and Neck Cancer

Recommendation	Level of Evidence	Degree of Recommendation
SECTION 7. Head and Neck Surgery—Larynx		
Recommendation 26		
Either surgery or radiotherapy is indicated for T1 and T2 laryngeal SCC, and both have similar oncological results. In general, surgery, especially transoral laser resection (if technically possible), provides a low rate of local recurrence and a high rate of laryngeal preservation; however, radiotherapy may offer better vocal results. The choice of treatment modality for these tumors should be discussed with the patient	1	C
Recommendation 27		
When surgical treatment is considered, the preferred surgical treatment for T1b laryngeal SCC is transoral laser resection. In patients with inadequate exposure, frontolateral vertical laryngectomy is also an option	1	B
Recommendation 28		
The current indications for open partial laryngectomies are laryngeal tumors with inadequate transoral exposure and certain tumors of the anterior commissure with vertical extension. Partial laryngectomy should be used in selected patients requiring salvage surgical therapy for a recurrent or persistent laryngeal tumor after radiotherapy failure	1	B
SECTION 8. Head and Neck Surgery—Larynx/Hypopharynx		
Recommendation 29		
Elderly patients with laryngeal carcinoma should be treated with curative intention. Their general condition and health as well as the stage of disease should be considered. Chronological age itself is not a reason to treat elderly patients differently; however, the elderly is generally affected by more comorbidities than younger patients and are prone to more postoperative complications. A careful preoperative evaluation and adequate communication with the patient are essential	4	B
Recommendation 30		
Nonsurgical organ preservation treatment should be performed in selected cases of laryngeal or hypopharyngeal SCC, ideally, in patients in whom a partial laryngectomy is not possible and in patients with stage T3 and low-volume stage T4a tumors with preserved larynx but candidate to total laryngectomy. Total laryngectomy is indicated in cases of laryngeal dysfunction, extensive highly infiltrative tumors with gross invasion of the cartilage and extralaryngeal extravasation, and local failure after nonsurgical organ preservation protocols. The patient's priorities should always be respected	1	B
Recommendation 31		
For stage T1 and T2 N0 supraglottic tumors in ventricular bands or ventricles and tumors that do not approach the midline, ipsilateral elective neck dissection of at least levels IIA and III is recommended	2	B
For stage T1 and T2 N0 supraglottic tumors in the epiglottis or aryepiglottic fold and tumors that approach the midline, bilateral elective neck dissection of at least levels IIA and III is recommended	2	B
For stage T3 and T4 N0 supraglottic tumors, bilateral elective neck dissection of levels IIA, III, and IV is recommended, and dissection of the anterior compartment and thyroidectomy should be considered in cases with extension to the paraglottic space	1	A
Recommendation 32		
Central compartment dissection (level VI) and thyroidectomy with preservation of the parathyroid glands or autotransplantation should be performed in the following patients with laryngeal and/or hypopharyngeal cancer: (1) Primary or subglottic extension: central compartment dissection of both sides + partial or total thyroidectomy; (2) Advanced glottic SCC (T3-T4), particularly those with involvement of the anterior commissure, cricoid cartilage, and/or subglottic extension: central compartment dissection ipsilateral to the lesion side and ipsilateral partial thyroidectomy or bilateral and total thyroidectomy in tumors extending to both sides; (3) Advanced supraglottic SCC (T3-T4), particularly those with involvement of the ventricle/paraglottic space, anterior commissure, and/or with lymph node metastases in lateral compartment of the neck: central compartment dissection ipsilateral to the lesion side and ipsilateral partial thyroidectomy or bilateral and total thyroidectomy in tumors extending to both sides; (4) Hypopharyngeal SCC: central compartment dissection ipsilateral to the side of the lesion or bilateral in tumors extending to both sides	1	B
SECTION 9. Clinical Oncology—Larynx/Hypopharynx		
Recommendation 33		
Combined chemotherapy and radiation therapy should be offered to patients with T2 hypopharyngeal SCC with lymph node involvement who are candidates for organ preservation	1	B
There is insufficient evidence from randomized studies to support the use of chemotherapy for T2N0 hypopharyngeal carcinomas, and radiation therapy alone remains the standard approach, even though many institutions routinely recommend concurrent chemoradiation therapy in this setting	4	D
Recommendation 34		
Once a week cisplatin at a dose of 40 mg/m ² may be given concurrently with radiation therapy for stage T3 laryngeal/hypopharyngeal SCCs, but the recommendation is extrapolated from evidence generated in the setting of adjuvant therapy or from studies that were not specifically focused on organ preservation. A more favorable toxicity profile with the once a week approach is applicable for resource-constrained healthcare systems; however, the infrastructure for once a week infusions may not be available to all patients, and the cost-effectiveness of this strategy has not yet been specifically evaluated	2	C

(continued on following page)

TABLE 5. Recommendations Regarding the Management of Patients With Larynx and/or Hypopharynx Squamous Cell Carcinoma and the Management of Recurrent or Metastatic Head and Neck Cancer (continued)

Recommendation	Level of Evidence	Degree of Recommendation
Recommendation 35		
At present, we do not recommend nonsurgical organ preservation strategies for patients with T4 laryngeal or hypopharyngeal carcinomas with gross thyroid cartilage invasion or with > 1-cm tongue base extension	2	A
Patients with T4 tumors due to other features may be candidates for organ preservation strategies on a case-by-case basis after thorough discussion of the goals of care and risks and benefits of surgical versus nonsurgical approaches in the setting of limited data	3	D
Quality of life, contemplating since the beginning what should be offered for rehabilitation, and the presence of comorbidities should be considered, as well as tumor stage, during the management plan	4	D
Recommendation 36		
There is insufficient evidence to support the superiority of concurrent chemoradiation therapy versus induction chemotherapy followed by radiation therapy, and we consider either one of these approaches to be equally reasonable as an organ preservation strategy for locally advanced laryngeal or hypopharyngeal cancers, balancing oncological results, quality of life, and patients' status	1	B
Recommendation 37		
Cetuximab given concurrently with radiation therapy may be considered for patients with laryngeal and hypopharyngeal SCC who are unfit for cisplatin, but it is not mandatory (given lack of robust evidence, the use of cetuximab in this setting should be carefully weighed against its costs in resource-constrained countries)	3	C
SECTION 10. Clinical Oncology—Head and Neck Cancer—Recurrent and metastatic disease		
Recommendation 38		
For patients with HNSCC who have experienced progression or recurrence over 6 months after definitive or adjuvant cisplatin-based chemoradiation and have an ECOG-PS of 0-1, the panel recommends chemotherapy plus cetuximab for patients with a CPS <1, chemotherapy plus pembrolizumab for those with an intermediate CPS (1-19), and pembrolizumab or chemotherapy plus pembrolizumab for those with a high CPS (≥20)	1	A
Second-line therapy options include nivolumab for patients who have progressed with chemotherapy and cetuximab within 6 months (platinum-refractory disease) and are immunotherapy-naïve	1	A
Cetuximab-chemotherapy regimens for immunotherapy experienced patients. In both scenarios, clinical trial enrollment is strongly encouraged based on availability	2	A
Recommendation 39		
There is little evidence regarding treatment of patients with an ECOG PS of 2 and HNSCC. Evaluation of the PD-L1 CPS can be considered. For CPS-positive patients, pembrolizumab monotherapy can be an option. Selected CPS-negative patients can be considered for chemotherapy or cetuximab monotherapy	3	C

Abbreviations: CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head and neck squamous cell carcinoma; SCC, squamous cell carcinoma.

Combined chemotherapy and radiation therapy are recommended for patients with T2 tumors with lymph node involvement who are eligible for organ preservation. For T2N0 hypopharyngeal carcinomas, there are not enough data to endorse chemotherapy. Standard practice continues to be radiation therapy alone although some institutions routinely advise concurrent chemoradiation therapy in such cases.^{206,207,249-256}

For stage T3 tumors, concurrent once a week cisplatin at a dose of 40 mg/m² with radiation therapy is the recommended treatment. The once a week approach offers a more favorable toxicity profile.^{100,207,257,258}

Currently, we do not recommend nonsurgical organ preservation strategies for patients with T4 carcinomas that exhibit gross thyroid cartilage invasion or tongue base extension exceeding 1 cm.^{206,207,259-263}

There is insufficient evidence to establish the superiority of concurrent chemoradiation over induction chemotherapy

followed by radiation therapy. Therefore, both approaches are equally reasonable as organ preservation strategies for locally advanced cancers.^{206,207,251,252,264}

Cetuximab, combined with radiation therapy, can be an option for patients who cannot tolerate cisplatin, but it is not obligatory. Because of the limited strong evidence, the decision to use cetuximab in such cases should be made thoughtfully, considering the costs.^{107,265}

Section 10. Clinical Oncology—Head and Neck Cancer—Recurrent and Metastatic Disease

The aim of this section is to present the evidence of the systemic treatment for recurrent and metastatic HNSCC including a discussion about patients living in a resource-constrained environment, as demonstrated in Table 5.

For patients with HNSCC experiencing recurrence more than 6 months after cisplatin-based chemoradiation with an Eastern Cooperative Oncology Group performance status (ECOG PS) of

0–1, the following recommendations apply: chemotherapy plus cetuximab (combined positive score [CPS] <1), chemotherapy plus pembrolizumab (CPS 1–19), and pembrolizumab alone or chemotherapy plus pembrolizumab (CPS ≥20). Second-line therapy options include nivolumab for patients who have progressed with chemotherapy and cetuximab within 6 months (platinum-refractory disease) and are immunotherapy-naïve. Cetuximab-chemotherapy regimens are for immunotherapy-experienced patients.^{111,266–269}

Limited evidence exists for treating patients with HNSCC with an ECOG PS of 2. Evaluating the PD-L1 CPS can be helpful. For CPS-positive patients, pembrolizumab as monotherapy can be considered. Selected CPS-negative patients may be candidates for chemotherapy or cetuximab monotherapy.^{270–276}

Section 11. Head and Neck Surgery—Reconstruction and Rehabilitation

The aim of this section is to present evidence of reconstruction and rehabilitation after oncologic resection of head and neck cancers, considering the availability of resources. Recommendations are described in [Table 6](#).

Free-flap reconstruction is essential when vital structures need coverage, particularly when reliable local or regional flaps are not viable options. Surgeons should consider free-flap reconstruction in cases such as anterior segmental mandibulectomy, maxillectomy without an obturator prosthesis, implant coverage, reconstruction failure with other flaps, and when aiming for optimal functional and aesthetic outcomes.^{277,278}

Pharyngeal reconstruction is imperative in cases of circumferential defects or when primary closure might lead to stenosis. In salvage operations, the use of a muscular flap over the suture line can be considered to minimize the risk of postoperative complications.^{279,280} Phonatory rehabilitation is essential for all total laryngectomy patients.²⁸¹

Section 12. Radiation Therapy

The aim of this section is to describe the evolution of external radiation therapy techniques, simulation, target volumes and treatment deintensification, dose and treatment planning, time to initiate treatment, and physician evaluation, as demonstrated in [Table 6](#).

Intensity modulated radiotherapy (IMRT) is the standard treatment because of its significant reduction in radiation exposure to nearby healthy tissue, minimizing side effects. For early-stage laryngeal cancer, the standard approach is still the three-dimensional conformal technique.^{282–285}

CT scan thickness should not exceed 3 mm. Outside the target volume, a slice thickness of up to 5 mm is acceptable.

Although not obligatory, the use of intravenous CT contrast agents is recommended.^{286–289}

Target volumes and organs at risk should be defined following international guidelines. A crucial step involves the review of target volumes by two radiation oncologists as part of a double-checking process.^{288,290–296}

When patients receive chemoradiation, the standard radiation therapy dose follows conventional fractionation. The potential advantages of combining concurrent chemotherapy with altered fractionation are not fully established. Early stage glottic cancer typically adheres to moderate hypofractionation for standard fractionation. The widely accepted dose distribution for the planning target volume (PTV) focuses on D95%/100 of the PTV.^{159,297–309}

Image-guided radiation therapy (IGRT) minimizes geometric uncertainties, reducing the risk of undertreating the target and damaging adjacent organs. For departments using a 5-mm clinical target volume-PTV margin expansion, daily and alternate-day IGRTs are advised. Departments not using daily IGRT should consider wider margins, exceeding 5 mm. In cases where residual errors persist in daily/alternate-day IGRT or when there is suspicion of volumetric tumor changes requiring treatment adaptation, three-dimensional volumetric imaging may be necessary.^{310–327}

Delays in starting or completing radiation therapy reduce survival and increase local relapse. The recommended timeframe for commencing curative radiotherapy is typically within 30 days of diagnosis. For postoperative radiation therapy, treatment should initiate within 4–6 weeks post-surgery. To prevent treatment disruptions and their impact on oncologic outcomes, weekly evaluations of the patients are essential.^{328–334}

In conclusion, this study was conducted on the basis of a consensus using a modified Delphi methodology that has also been applied in similar studies worldwide.⁷ However, there are intrinsic limitations that should be addressed.

First, we did not conduct a comparison or an adaptation of already published guidelines. From the outset, the objective of this study was to establish specific recommendations tailored to the context of Latin America and other regions with limited resources, while focusing on the best available evidence. Simply adapting a guideline designed for another context might deviate from our intended focus but could lead to potential pitfalls because of insufficient evidence.

Second, although the stakeholders involved in the process were recognized national leaders in the field, unfortunately, many others were not included in the study. To mitigate any bias in this selection, all recommendations underwent validation by the entire panel, as detailed in the Methods section.

TABLE 6. Recommendations Regarding Reconstruction and Rehabilitation and Radiation Therapy for Patients With Head and Neck Squamous Cancer

Recommendation	Level of Evidence	Degree of Recommendation
SECTION 11. Head and Neck Surgery—Reconstruction and Rehabilitation		
Recommendation 40		
Free-flap reconstruction is indispensable when there is the need for coverage vital structures, especially in the absence of reliable local or regional flaps as alternatives. The surgeon must consider a free-flap reconstruction for anterior segmental mandibulectomy, after a maxillectomy without an obturator prosthesis, to cover implants, in cases of reconstruction failure with other regional or local flaps, and to obtain the best functional and aesthetic results	4	C
Recommendation 41		
Pharyngeal reconstruction is necessary when there is a circumferential defect or when primary closure will result in stenosis that can increase the risk of salivary fistula formation, especially in salvage surgeries. The interposition of a muscular flap over the suture line could also be performed to reduce the risk of major postoperative complications, mainly in salvage operations	1	B
Recommendation 42		
All patients should receive phonatory rehabilitation after a total laryngectomy. The valved voice prosthesis is the best method to achieve improved quality and fluency of speech. An electrolarynx is an option for immediate rehabilitation, and esophageal speech could also be tried, especially when there is no other resource available	4	B
SECTION 12. Radiation Therapy		
Recommendation 43		
IMRT is the standard of care as it notably reduces the dose to neighboring normal tissue and reduces side effect	1	A
For early-stage laryngeal cancer, 3DCRT remains the standard approach	4	B
Recommendation 44		
The CT scan thickness must be ≤ 3 mm throughout the region that contains the target volumes at simulation. Regions outside the target volume may be scanned with a slice thickness ≤ 5 mm. The use of intravenous CT contrast agents is not mandatory but is recommended	4	C
Recommendation 45		
Target volumes and organs at risk should be defined based on international guidelines. It is essential that the target volumes be reviewed by two different radiation oncologists (double-checking process)	4	C
There are no available phase 3 studies to support these deintensification strategies in clinical practice	1	A
Recommendation 46		
When patients are treated with radiation therapy concomitant with chemotherapy for both, radical or postoperative settings, the standard radiation therapy dose is the conventional fractionation	1	A
The benefit of the association of concurrent chemotherapy with altered fractionation has not yet been completely defined	1	B
The standard fractionation for early-stage glottic cancer is moderate hypofractionation	1	A
The most accepted dose distribution to the PTV is D95%/100 of the PTV	4	C
The peer review process is an essential part of quality assurance	4	C
Recommendation 47		
IGRT is an essential component for delivering radiation therapy due to its ability to reduce geometric uncertainties and the risk of undertreating the target volume and overtreating adjacent organs at risk. Daily and alternate-day IGRTs are recommended for services that apply a 5-mm CTV-PTV margins expansion. Margins larger than 5 mm are recommended for departments that avoid daily IGRT. Three-dimensional volumetric imaging may be necessary to remove residual errors in daily/alternating IGRT or when there is a suspicion of volumetric tumor changes, and some action to adapt the treatment is necessary	4	C
Recommendation 48		
Delays in starting or completing radiation therapy have been associated with decreased survival and increased local relapse. The most accepted time for starting curative radiotherapy is 30 days after the diagnosis. In the setting of postoperative radiation therapy, the treatment should begin within four or 6 weeks postoperatively. Each day of treatment interruption can be associated with a 1.4% decrease in local control. Moreover, 5 days of prolonged OTT was associated with a 3.5% decline in the 2-year local control rate. To avoid treatment interruptions and their impact on the oncological outcomes, it is essential to evaluate patients with head and neck cancer weekly	4	C

Abbreviations: 3DCRT, three-dimensional conformal technique; CT, computed tomography; CTV, clinical target volume; IGRT, image-guided radiation therapy; IMRT, intensity modulated radiotherapy; OTT, overall treatment time; PTV, planning target volume.

Third, no patients or patients' representatives were directly included in the study. However, the GBCP (Brazilian Group of Head and Neck Cancer) is a multidisciplinary organization of health care professionals specializing in assisting patients with head and neck cancer and advocating for patient rights. The entire board of GBCP directors contributed to this study's authorship, ensuring consideration for the patients' best interests in adapting the best evidence to the Latin American context and aiming to minimize potential biases.

Finally, we established 48 recommendations on the basis of the Latin American context without aiming to provide a

stratification of different possibilities according to resource settings or other variables such as availability or physicians' expertise, for example. Readers should consider these limitations when applying the recommendations to their clinical scenarios.

The present consensus established 48 recommendations on care of patients with HNSCC considering the availability of resources and focusing on oncologic benefit in the reality of Latin America. These recommendations could also be used to formulate treatment strategies for other regions with similar situations to Latin America countries.

AFFILIATIONS

¹Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP), São Paulo, Brazil

²Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil

³Universidade de São Paulo (FMUSP), São Paulo, Brazil

⁴DOM Oncologia, Divinópolis, Brazil

⁵Head and Neck Cancer Reference Center—AC Camargo Cancer Center, São Paulo, Brazil

⁶Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil

⁷A C Camargo Cancer Center, São Paulo, Brazil

⁸Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP), São Paulo, Brazil

⁹National Cancer Institute, Rio de Janeiro, Brazil

¹⁰INEN-AUNA, Lima, Peru

¹¹Head and Neck Surgeon, Lima, Peru

¹²Barretos Cancer Hospital, Barretos, Brazil

¹³University of São Paulo School of Medicine, São Paulo, Brazil

¹⁴Hospital das Clínicas, Universidade de São Paulo (HCFMUSP), São Paulo, Brazil

¹⁵Brazilian National Cancer Institute, Rio de Janeiro, Brazil

¹⁶Profesor Adjunto Catedra de Otorrinolaringología del Hospital de Clínicas, Montevideo, Uruguay

¹⁷Instituto Alexander Fleming, Buenos Aires, Argentina

¹⁸Centro de Radioterapia Dean Funes, Córdoba, Argentina

¹⁹Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia

²⁰Juravinski Cancer Centre, Department of Oncology, Division of Radiation Oncology, McMaster University, Hamilton, ON, Canada

²¹Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP), São Paulo, Brazil

²²AC Camargo Cancer Center and Hospital Albert Einstein, São Paulo, Brazil

²³Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil

²⁴Grupo Oncoclínicas, Rio de Janeiro, Brazil

²⁵Department of Pathology, University of Sao Paulo School of Medicine, São Paulo, Brazil

²⁶University of Pernambuco (UPE), Recife, Brazil

²⁷Department of Surgical Oncology and Head and Neck Surgery, Division of Surgery, P. Universidad Católica de Chile, Santiago, Chile

²⁸Grupo Oncoclínicas, Salvador, Brazil

²⁹Department of Oncology—Queen's University, Kingston, Canada

³⁰Oncoclínicas Recife e Hospital Santa Águeda, Caruaru, Brazil

³¹Head and Neck Surgeon, Rosario, Argentina

³²Medicasur, Mexico City, Mexico

³³Instituto Nacional del Cancer, Hospital de Clinicas, Asunción, Paraguay

³⁴Department of Surgery, Universidad de Antioquia, Hospital Alma Mater, Medellín, Colombia

³⁵ESMO Member, Peruvian Society of Medical Oncology (S.P.O.M.) Member, La Molina, Peru

³⁶Head and Neck Surgery and Otorhinolaryngology Department, A. C. Camargo Cancer Center, São Paulo, Brazil

³⁷Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil

³⁸Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile

³⁹The University of Texas MD Anderson Cancer Center, Houston, TX

⁴⁰University of Glasgow, Glasgow, Scotland

⁴¹International Agency for Research on Cancer (IARC/WHO), Genomic Epidemiology Branch, Lyon, France

CORRESPONDING AUTHOR

Leandro Luongo Matos, MD, PhD; e-mail: l.matos@fm.usp.br.

DISCLAIMER

Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/WHO. The authors declare that this paper was elaborated in the absence of any commercial or financial relationships that could be considered as a potential conflict of interest.

SUPPORT

Supported by the Latin American Cooperative Oncology (LACOG) Group, Brazilian Head and Neck Surgery Society (SBCCP—Sociedade Brasileira de Cirurgia de Cabeça e Pescoço), and Brazilian Head and Neck Cancer Group (GBCP—Grupo Brasileiro de Câncer Cabeça e Pescoço). This work is also part of the HEADSpAcE study (Translational studies of HEAD and neck cancer in South America and Europe). This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant No 825771 (recipient M.P.C.).

AUTHOR CONTRIBUTIONS

Conception and design: Leandro Luongo Matos, Luiz Paulo Kowalski, Aline Lauda Freitas Chaves, Thiago Bueno de Oliveira, Gustavo Nader Marta, Maria Paula Curado, Mario Avila Cabrera, Genival Barbosa de Carvalho, Andre Guimarães Gouveia, Alexandre Arthur Jacinto, Renan Bezerra Lira, Fátima Cristina Mendes de Matos, Fabio Ynoe de Moraes, Diego Chaves Rezende Moraes, José Guilherme Vartanian, Gustavo Viani, Paul Brennan

Administrative support: Luiz Paulo Kowalski, Mario Avila Cabrera, Genival Barbosa de Carvalho, Fátima Cristina Mendes de Matos

Provision of study materials or patients: Maria Paula Curado, Terence P. Farias, Gustavo Sarria Bardales, Mario Avila Cabrera, Andrés Munyo Estefan, Gustavo Alberto Ferraris, Marco Aurelio Vamondes Kulcsar, Evandro Sobroza de Mello, Fátima Cristina Mendes de Matos, Adela Poitevin, José Guilherme Vartanian, Gustavo Viani

Collection and assembly of data: Leandro Luongo Matos, Aline Lauda Freitas Chaves, Gustavo Nader Marta, Gilberto de Castro Junior, Terence P. Farias, Gustavo Sarria Bardales, Mario Avila Cabrera, Renato de Castro Capuzzo, Rogério Aparecido Dedivitis, Andrés Munyo Estefan, Agustin Horacio Falco, Gustavo Alberto Ferraris, Alejandro Gonzalez-Motta, Andre Guimarães Gouveia, Alexandre Arthur Jacinto, Ana Kober Leite, Pedro De Marchi, Evandro Sobroza de Mello, Fátima Cristina Mendes de Matos, Pablo H. Montero, Eduardo Dias de Moraes, Fernando Miguel Poenitz, Adela Poitevin, Miguel Ticona-Castro, José Guilherme Vartanian, Eugenio F. Vines, William Nassib William Junior, Shama Virani, Paul Brennan

Data analysis and interpretation: Leandro Luongo Matos, Luiz Paulo Kowalski, Aline Lauda Freitas Chaves, Gustavo Nader Marta, Gilberto de Castro Junior, Mario Avila Cabrera, Claudio Roberto Cernea, Fernando

Luiz Dias, Alejandro Gonzalez-Motta, Alexandre Arthur Jacinto, Marco Aurelio Vamondes Kulcsar, Milena Perez Mak, Pablo H. Montero, Fabio Ynoe de Moraes, Hernán Ortiz Riveros, Álvaro Sanabria, William Nassib William Junior, David Conway, Paul Brennan

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments.org)).

No potential conflicts of interest were reported.

ACKNOWLEDGMENT

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825771.

REFERENCES

- d'Alessandro AF, Pinto FR, Lin CS, et al: Oral cavity squamous cell carcinoma: Factors related to occult lymph node metastasis. *Braz J Otorhinolaryngo* 181:248-254, 2015
- Pinto FR, Matos LL, Gumz Segundo W, et al: Tobacco and alcohol use after head and neck cancer treatment: Influence of the type of oncological treatment employed. *Rev Assoc Med Bras* (1992) 57:171-176, 2011
- Bouvard V, Nathan ST, Singh D, et al: IARC perspective on oral cancer prevention. *N Engl J Med* 387:1999-2005, 2022
- Chaturvedi P, Singavi H, Malik A, et al: Outcome of head and neck squamous cell cancers in low-resource settings: Challenges and opportunities. *Otolaryngol Clin North Am* 51:619-629, 2018
- Joshi P, Dutta S, Chaturvedi P, et al: Head and neck cancers in developing countries. *Rambam Maimonides Med J* 5:e0009, 2014
- Kowalski LP, Sanabria A: Priority setting in head and neck oncology in low-resource environments. *Curr Opin Otolaryngol Head Neck Surg* 27:198-202, 2019
- Hsu C, Sanford B: The Delphi technique: Making sense of consensus. *Pract Assess Res Eval* 12:1-9, 2007
- Uribe S, Rojas LA, Rosas CF: Accuracy of imaging methods for detection of bone tissue invasion in patients with oral squamous cell carcinoma. *Dentomaxillofac Radiol* 42:20120346, 2013
- Bombeccari GP, Candonato V, Gianni AB, et al: Accuracy of the cone beam computed tomography in the detection of bone invasion in patients with oral cancer: A systematic review. *Eurasian J Med* 51:298-306, 2019
- Brandão Neto Jds, Aires FT, Dedivitis RA, et al: Comparison between magnetic resonance and computed tomography in detecting mandibular invasion in oral cancer: A systematic review and diagnostic meta-analysis: MRI x CT in mandibular invasion. *Oral Oncol* 78:114-118, 2018
- Kouketsu A, Miyashita H, Kojima I, et al: Comparison of different diagnostic imaging techniques for the detection of bone invasion in oral cancers. *Oral Oncol* 120:105453, 2021
- van den Brekel MW, Stel HV, Castelijns JA, et al: Lymph node staging in patients with clinically negative neck examinations by ultrasound and ultrasound-guided aspiration cytology. *Am J Surg* 162:362-366, 1991
- Takes RP, Righi P, Meeuwis CA, et al: The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. *Int J Radiat Oncol Biol Phys* 40:1027-1032, 1998
- Prehn RB, Pasic TR, Harari PM, et al: Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. *Otolaryngol Head Neck Surg* 119:628-633, 1998
- Abdel-Halim CN, Rosenberg T, Dyrvig AK, et al: Diagnostic accuracy of imaging modalities in detection of histopathological extranodal extension: A systematic review and meta-analysis. *Oral Oncol* 114:105169, 2021
- Park SJ, Guenette JP, Suh CH, et al: The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: A systematic review and diagnostic meta-analysis. *Eur Radiol* 31:2048-2061, 2021
- Garavello W, Ciardo A, Spreafico R, et al: Risk factors for distant metastases in head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 132:762-766, 2006
- Liu X, Wang S, Wu W, et al: A nomogram for prediction of distant metastasis in patients with hypopharyngeal squamous cell carcinoma: A study based on the SEER database. *Am J Transl Res* 14:5409-5419, 2022
- de Bree R, Deurloo EE, Snow GB, et al: Screening for distant metastases in patients with head and neck cancer. *Laryngoscope* 110:397-401, 2000
- Troell RJ, Terris DJ: Detection of metastases from head and neck cancers. *Laryngoscope* 105:247-250, 1995
- Fleming AJ Jr, Smith SP Jr, Paul CM, et al: Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. *Laryngoscope* 117:1173-1179, 2007
- Kim SY, Roh JL, Yeo NK, et al: Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. *Ann Oncol* 18:1698-1703, 2007
- Senft A, de Bree R, Hoekstra QS, et al: Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. *Radiother Oncol* 87:221-229, 2008
- Zanation AM, Sutton DK, Couch ME, et al: Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. *Laryngoscope* 115:1186-1190, 2005
- De Cicco R, de Melo Menezes R, Nicolau UR, et al: Impact of human papillomavirus status on survival and recurrence in a geographic region with a low prevalence of HPV-related cancer: A retrospective cohort study. *Head Neck* 42:93-102, 2020

26. Haughey BH, Gates GA, Arfken CL, et al: Meta-analysis of second malignant tumors in head and neck cancer: The case for an endoscopic screening protocol. *Ann Otol Rhinol Laryngol* 101: 105-112, 1992
27. Davidson J, Gilbert R, Irish J, et al: The role of panendoscopy in the management of mucosal head and neck malignancy-a prospective evaluation. *Head Neck* 22:449-455, 2000; discussion 454-455
28. US Preventive Services Task Force; Krist AH, Davidson KW, et al: Screening for lung cancer: US Preventive Services Task Force recommendation statement. *JAMA* 325:962-970, 2021
29. Ng SP, Pollard C 3rd, Kamal M, et al: Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. *NPJ Precis Oncol* 3:22, 2019
30. Rennemo E, Zatterstrom U, Boysen M: Impact of second primary tumors on survival in head and neck cancer: An analysis of 2,063 cases. *Laryngoscope* 118:1350-1356, 2008
31. Buchakjian MR, Tasche KK, Robinson RA, et al: Association of main specimen and tumor bed margin status with local recurrence and survival in oral cancer surgery. *JAMA Otolaryngol Head Neck Surg* 142:1191-1198, 2016
32. Demir B, Incac S, Uckuyulu EI, et al: Accuracy of frozen section examination in oral cavity cancers. *Ear Nose Throat J* 101:NP354-NP357, 2022
33. Tirelli G, Hinni ML, Fernandez-Fernandez MM, et al: Frozen sections and complete resection in oral cancer surgery. *Oral Dis* 25:1309-1317, 2019
34. Layfield EM, Schmidt RL, Esebua M, et al: Frozen section evaluation of margin status in primary squamous cell carcinomas of the head and neck: A correlation study of frozen section and final diagnoses. *Head Neck Pathol* 12:175-180, 2018
35. Amit M, Na'ara S, Leider-Trejo L, et al: Improving the rate of negative margins after surgery for oral cavity squamous cell carcinoma: A prospective randomized controlled study. *Head Neck* 38: E1803-E1809, 2016 (suppl 1)
36. Robinson EM, Lam AS, Solomon I, et al: Trends in positive surgical margins in cT1-T2 oral cavity squamous cell carcinoma. *Laryngoscope* 132:1962-1970, 2022
37. Luryi AL, Chen MM, Mehra S, et al: Positive surgical margins in early stage oral cavity cancer: An analysis of 20,602 cases. *Otolaryngol Head Neck Surg* 151:984-990, 2014
38. Datta S, Mishra A, Chaturvedi P, et al: Frozen section is not cost beneficial for the assessment of margins in oral cancer. *Indian J Cancer* 56:19-23, 2019
39. Mair M, Nair D, Nair S, et al: Intraoperative gross examination vs frozen section for achievement of adequate margin in oral cancer surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol* 123:544-549, 2017
40. Chaturvedi P, Datta S, Nair S, et al: Gross examination by the surgeon as an alternative to frozen section for assessment of adequacy of surgical margin in head and neck squamous cell carcinoma. *Head Neck* 36:557-563, 2014
41. van Lanschot CGF, Mast H, Hardillo JA, et al: Relocation of inadequate resection margins in the wound bed during oral cavity oncological surgery: A feasibility study. *Head Neck* 41:2159-2166, 2019
42. Bulbul MG, Tarabichi O, Sethi RK, et al: Does clearance of positive margins improve local control in oral cavity cancer? A meta-analysis. *Otolaryngol Head Neck Surg* 161:235-244, 2019
43. Meier JD, Oliver DA, Varvares MA: Surgical margin determination in head and neck oncology: Current clinical practice. The results of an International American Head and Neck Society Member Survey. *Head Neck* 27:952-958, 2005
44. Bulbul MG, Zenga J, Tarabichi O, et al: Margin practices in oral cavity cancer resections: Survey of American Head and Neck Society Members. *Laryngoscope* 131:782-787, 2021
45. Horwich P, Mackay C, Bullock M, et al: Specimen oriented intraoperative margin assessment in oral cavity and oropharyngeal squamous cell carcinoma. *J Otolaryngol Head Neck Surg* 50:37, 2021
46. Maxwell JH, Thompson LD, Brandwein-Gensler MS, et al: Early oral tongue squamous cell carcinoma: Sampling of margins from tumor bed and worse local control. *JAMA Otolaryngol Head Neck Surg* 141:1104-1110, 2015
47. Umstadat LA, Mills JC, Critchlow WA, et al: Shrinkage in oral squamous cell carcinoma: An analysis of tumor and margin measurements in vivo, post-resection, and post-formalin fixation. *Am J Otolaryngol* 38:660-662, 2017
48. Black C, Marotti J, Zarovnya E, et al: Critical evaluation of frozen section margins in head and neck cancer resections. *Cancer* 107:2792-2800, 2006
49. Brouwer de Koning SG, Schaeffers A, Schats W, et al: Assessment of the deep resection margin during oral cancer surgery: A systematic review. *Eur J Surg Oncol* 47:2220-2232, 2021
50. Barroso EM, Aaboubout Y, van der Sar LC, et al: Performance of intraoperative assessment of resection margins in oral cancer surgery: A review of literature. *Front Oncol* 11:628297, 2021
51. Kerker FA, Adler W, Brunner K, et al: Anatomical locations in the oral cavity where surgical resections of oral squamous cell carcinomas are associated with a close or positive margin-a retrospective study. *Clin Oral Investig* 22:1625-1630, 2018
52. Tirelli G, Boscolo Nata F, Gatto A, et al: Intraoperative margin control in transoral approach for oral and oropharyngeal cancer. *Laryngoscope* 129:1810-1815, 2019
53. Gorpe P, Simon C: A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. *Oral Oncol* 98:69-77, 2019
54. Fiz I, Mazzola F, Fiz F, et al: Impact of close and positive margins in transoral laser microsurgery for Tis-T2 glottic cancer. *Front Oncol* 7:245, 2017
55. Bajwa MS, Houghton D, Java K, et al: The relevance of surgical margins in clinically early oral squamous cell carcinoma. *Oral Oncol* 110:104913, 2020
56. Alicandri-Ciufelli M, Bonali M, Piccinini A, et al: Surgical margins in head and neck squamous cell carcinoma: What is 'close'? *Eur Arch Otorhinolaryngol* 270:2603-2609, 2013
57. Weinstock YE, Alava I 3rd, Dierks EJ: Pitfalls in determining head and neck surgical margins. *Oral Maxillofac Surg Clin North Am* 26:151-162, 2014
58. Holcomb AJ, Herberg M, Strohl M, et al: Impact of surgical margins on local control in patients undergoing single-modality transoral robotic surgery for HPV-related oropharyngeal squamous cell carcinoma. *Head Neck* 43:2434-2444, 2021
59. Bungum A, Jensen JS, Jakobsen KK, et al: Impact of surgical resection margins less than 5 mm in oral cavity squamous cell carcinoma: A systematic review. *Acta Otolaryngol* 140:869-875, 2020
60. Zanon DK, Migliacci JC, Xu B, et al: A proposal to redefine close surgical margins in squamous cell carcinoma of the oral tongue. *JAMA Otolaryngol Head Neck Surg* 143:555-560, 2017
61. Hamman J, Howe CL, Borgstrom M, et al: Impact of close margins in head and neck mucosal squamous cell carcinoma: A systematic review. *Laryngoscope* 132:307-321, 2022
62. Anderson CR, Sisson K, Moncrieff M: A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma. *Oral Oncol* 51:464-469, 2015
63. Lewis JS Jr, Beadle B, Bishop JA, et al: Human papillomavirus testing in head and neck carcinomas: Guideline from the College of American Pathologists. *Arch Pathol Lab Med* 142:559-597, 2018
64. Augustin JG, Lepine C, Morini A, et al: HPV detection in head and neck squamous cell carcinomas: What is the issue? *Front Oncol* 10:1751, 2020
65. Mehanna H, Taberna M, von Buchwald C, et al: Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): A multicentre, multinational, individual patient data analysis. *Lancet Oncol* 24:239-251, 2023
66. Zanon DK, Montero PH, Migliacci JC, et al: Survival outcomes after treatment of cancer of the oral cavity (1985-2015). *Oral Oncol* 90:115-121, 2019
67. D'Cruz AK, Vaish R, Kapre N, et al: Elective versus therapeutic neck dissection in node-negative oral cancer. *N Engl J Med* 373:521-529, 2015
68. Hutchison IL, Ridout F, Cheung SMY, et al: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. *Br J Cancer* 121:827-836, 2019
69. de Bree R, Takes RP, Shah JP, et al: Elective neck dissection in oral squamous cell carcinoma: Past, present and future. *Oral Oncol* 90:87-93, 2019
70. Koch WM, Choti MA, Civelek AC, et al: Gamma probe-directed biopsy of the sentinel node in oral squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 124:455-459, 1998
71. Garrel R, Poissonnet G, Moya Plana A, et al: Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. *J Clin Oncol* 38:4010-4018, 2020
72. Hasegawa Y, Tsukahara K, Yoshimoto S, et al: Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: A randomized, multicenter, and noninferiority trial. *J Clin Oncol* 39:2025-2036, 2021
73. de Bree R, de Keizer B: Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients. *Cancer* 127:1959-1962, 2021
74. Schilling C, Stoekli SJ, Vigili MG, et al: Surgical consensus guidelines on sentinel node biopsy (SNB) in patients with oral cancer. *Head Neck* 41:2655-2664, 2019
75. Friedman M, Lim JW, Dickey W, et al: Quantification of lymph nodes in selective neck dissection. *Laryngoscope* 109:368-370, 1999
76. Agrama MT, Reiter D, Cunnane MF, et al: Nodal yield in neck dissection and the likelihood of metastases. *Otolaryngol Head Neck Surg* 128:185-190, 2003
77. Ebrahimi A, Clark JR, Amit M, et al: Minimum nodal yield in oral squamous cell carcinoma: Defining the standard of care in a multicenter international pooled validation study. *Ann Surg Oncol* 21: 3049-3055, 2014
78. Lemieux A, Kedarisetty S, Raju S, et al: Lymph node yield as a predictor of survival in pathologically node negative oral cavity carcinoma. *Otolaryngol Head Neck Surg* 154:465-472, 2016
79. Divi V, Chen MM, Nussenbaum B, et al: Lymph node count from neck dissection predicts mortality in head and neck cancer. *J Clin Oncol* 34:3892-3897, 2016
80. Divi V, Harris J, Harari PM, et al: Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). *Cancer* 122:3464-3471, 2016
81. Robbins KT, Shaha AR, Medina JE, et al: Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg* 134:536-538, 2008
82. Bocca E, Pignataro O, Oldini C, et al: Functional neck dissection: An evaluation and review of 843 cases. *Laryngoscope* 94:942-945, 1984
83. Byers RM: Modified neck dissection. A study of 967 cases from 1970 to 1980. *Am J Surg* 150:414-421, 1985
84. Liang L, Zhang T, Kong Q, et al: A meta-analysis on selective versus comprehensive neck dissection in oral squamous cell carcinoma patients with clinically node-positive neck. *Oral Oncol* 51: 1076-1081, 2015
85. Andersen PE, Warren F, Spiro J, et al: Results of selective neck dissection in management of the node-positive neck. *Arch Otolaryngol Head Neck Surg* 128:1180-1184, 2002

86. Shimura S, Ogi K, Miyazaki A, et al: Selective neck dissection and survival in pathologically node-positive oral squamous cell carcinoma. *Cancers (Basel)* 11:269, 2019
87. Kokemueller H, Brachvogel P, Eckardt A, et al: Neck dissection in oral cancer—clinical review and analysis of prognostic factors. *Int J Oral Maxillofac Surg* 31:608-614, 2002
88. Kowalski LP, Carvalho AL: Feasibility of supraomohyoid neck dissection in N1 and N2a oral cancer patients. *Head Neck* 24:921-924, 2002
89. Bessell A, Glennly AM, Furness S, et al: Interventions for the treatment of oral and oropharyngeal cancers: Surgical treatment. *Cochrane Database Syst Rev* 9:CD006205, 2011
90. Rodrigo JP, Grilli G, Shah JP, et al: Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: Systematic review. *Eur J Surg Oncol* 44:395-403, 2018
91. Maharaj DD, Seenivasagam RK, Majumdar KS, et al: Analysis of the role of selective neck dissection in clinically node-positive T3/T4 oral cancers. *Biomed Res Int* 2022:2204745, 2022
92. Bernier J, Dorngeir C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 350:1945-1952, 2004
93. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 350:1937-1944, 2004
94. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). *Head Neck* 27:843-850, 2005
95. Hinni ML, Ferlito A, Brandwein-Gensler MS, et al: Surgical margins in head and neck cancer: A contemporary review. *Head Neck* 35:1362-1370, 2013
96. Cooper JS, Zhang Q, Pajak TF, et al: Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 84:1198-1205, 2012
97. Trifiletti DM, Smith A, Mitra N, et al: Beyond positive margins and extracapsular extension: Evaluating the utilization and clinical impact of postoperative chemoradiotherapy in resected locally advanced head and neck cancer. *J Clin Oncol* 35:1550-1560, 2017
98. Lu DJ, Luu M, Gay C, et al: Nodal metastasis count and oncologic outcomes in head and neck cancer: A secondary analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. *Int J Radiat Oncol Biol Phys* 113:787-795, 2022
99. Zumsteg ZS, Luu M, Kim S, et al: Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation. *Ann Oncol* 30:1669-1684, 2019
100. Kiyota N, Tahara M, Mizusawa J, et al: Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): A multicenter, noninferiority, phase II/III randomized controlled trial. *J Clin Oncol* 40:1980-1990, 2022
101. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. *J Clin Oncol* 21:327-333, 2003
102. Bossi P, Lo Vullo S, Guzzo M, et al: Preoperative chemotherapy in advanced resectable OCSCC: Long-term results of a randomized phase III trial. *Ann Oncol* 25:462-466, 2014
103. Zhong LP, Zhang CP, Ren GX, et al: Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *J Clin Oncol* 31:744-751, 2013
104. Marta GN, Riera R, Bossi P, et al: Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. *Eur J Cancer* 51:2596-2603, 2015
105. Patil VM, Noronha V, Joshi A, et al: Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference? *Indian J Cancer* 50:1-8, 2013
106. Rudresha AH, Chaudhuri T, Lakshmaiah KC, et al: Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: A regional cancer center experience. *Indian J Cancer* 54:35-38, 2017
107. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 354:567-578, 2006
108. Patil VM, Noronha V, Menon N, et al: Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. *J Clin Oncol* 41:2350-2361, 2023
109. Machtay M, Moughan J, Trotti A, et al: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. *J Clin Oncol* 26:3582-3589, 2008
110. Laccourreye O, Hans S, Menard M, et al: Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. *Arch Otolaryngol Head Neck Surg* 131:592-599, 2005
111. Ferris RL, Flamand Y, Weinstein GS, et al: Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). *J Clin Oncol* 40:138-149, 2022
112. Monnier Y, Simon C: Surgery versus radiotherapy for early oropharyngeal tumors: A never-ending debate. *Curr Treat Options Oncol* 16:42, 2015
113. Laccourreye O, Holsinger FC: A simple method to expose the surgical field when performing a thyroplasty. *Otolaryngol Head Neck Surg* 132:108-109, 2005
114. Roosli C, Tschudi DC, Studer G, et al: Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. *Laryngoscope* 119:534-540, 2009
115. Dias FL, Walder F, Leonhardt FD: The role of transoral robotic surgery in the management of oropharyngeal cancer. *Curr Opin Oncol* 29:166-171, 2017
116. Steiner W, Fierek O, Ambrosch P, et al: Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. *Arch Otolaryngol Head Neck Surg* 129:36-43, 2003
117. Howard J, Masterson L, Dwivedi RC, et al: Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. *Cochrane Database Syst Rev* 12:CD010963, 2016
118. Lorincz BB, Jowett N, Knecht R: Decision management in transoral robotic surgery: Indications, individual patient selection, and role in the multidisciplinary treatment for head and neck cancer from a European perspective. *Head Neck* 38:E2190-E2196, 2016 (suppl 1)
119. Upile NS, Shaw RJ, Jones TM, et al: Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. *Laryngoscope* 124:2739-2744, 2014
120. De Ceulaer J, De Clercq C, Swennen GR: Robotic surgery in oral and maxillofacial, craniofacial and head and neck surgery: A systematic review of the literature. *Int J Oral Maxillofac Surg* 41:1311-1324, 2012
121. Moore EJ, Hinni ML: Critical review: Transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer. *Int J Radiat Oncol Biol Phys* 85:1163-1167, 2013
122. Kelly K, Johnson-Obaseki S, Lumingu J, et al: Oncologic, functional and surgical outcomes of primary transoral robotic surgery for early squamous cell cancer of the oropharynx: A systematic review. *Oral Oncol* 50:696-703, 2014
123. Nichols AC, Yoo J, Hammond JA, et al: Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. trans-oral robotic surgery (ORATOR)—study protocol for a randomized phase II trial. *BMC Cancer* 13:133, 2013
124. Mehanna H, Evans M, Beasley M, et al: Oropharyngeal cancer: United Kingdom national multidisciplinary guidelines. *J Laryngol Otol* 130:S90-S96, 2016
125. Morisod B, Simon C: Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. *Head Neck* 38:E2143-E2150, 2016 (suppl 1)
126. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers. (ed v 2.22), 2022. <http://nccn.org>
127. Moore EJ, Olsen SM, Laborde RR, et al: Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. *Mayo Clin Proc* 87:219-225, 2012
128. de Almeida JR, Li R, Magnuson JS, et al: Oncologic outcomes after transoral robotic surgery: A multi-institutional study. *JAMA Otolaryngol Head Neck Surg* 141:1043-1051, 2015
129. Baskin RM, Boyce BJ, Amdur R, et al: Transoral robotic surgery for oropharyngeal cancer: Patient selection and special considerations. *Cancer Manag Res* 10:839-846, 2018
130. Baliga S, Kabarriri R, Jiang J, et al: Utilization of transoral robotic surgery (TORS) in patients with oropharyngeal squamous cell carcinoma and its impact on survival and use of chemotherapy. *Oral Oncol* 86:75-80, 2018
131. Zenga J, Wilson M, Adkins DR, et al: Treatment outcomes for T4 oropharyngeal squamous cell carcinoma. *JAMA Otolaryngol Head Neck Surg* 141:1118-1127, 2015
132. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 363:24-35, 2010
133. de Castro G Jr, Alves GV, Castro AF, et al: Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. *Crit Rev Oncol Hematol* 131:30-34, 2018
134. Mydlarz WK, Chan JY, Richmon JD: The role of surgery for HPV-associated head and neck cancer. *Oral Oncol* 51:305-313, 2015
135. Frenkel CH, Yang J, Zhang M, et al: Compared outcomes of concurrent versus staged transoral robotic surgery with neck dissection. *Otolaryngol Head Neck Surg* 157:791-797, 2017
136. Mockelmann N, Busch CJ, Munscher A, et al: Timing of neck dissection in patients undergoing transoral robotic surgery for head and neck cancer. *Eur J Surg Oncol* 41:773-778, 2015
137. Repanos C, Mirza AH, George M, et al: Timing of neck dissection in association with transoral surgery: A systematic review. *Head Neck* 39:1020-1032, 2017
138. Bollig CA, Gilley DR, Ahmad J, et al: Prophylactic arterial ligation following transoral robotic surgery: A systematic review and meta-analysis. *Head Neck* 42:739-746, 2020
139. Moore EJ, Olsen KD, Martin EJ: Concurrent neck dissection and transoral robotic surgery. *Laryngoscope* 121:541-544, 2011
140. Howard BE, Hinni ML, Nagel TH, et al: Submandibular gland preservation during concurrent neck dissection and transoral surgery for oropharyngeal squamous cell carcinoma. *Otolaryngol Head Neck Surg* 150:587-593, 2014
141. Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. *Cancer* 29:1446-1449, 1972

142. Shah JP, Candela FC, Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. *Cancer* 66:109-113, 1990
143. Koyfman SA, Ismaila N, Crook D, et al: Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline. *J Clin Oncol* 37:1753-1774, 2019
144. Lim YC, Koo BS, Lee JS, et al: Distributions of cervical lymph node metastases in oropharyngeal carcinoma: Therapeutic implications for the N0 neck. *Laryngoscope* 116:1148-1152, 2006
145. Sanguineti G, Califano J, Stafford E, et al: Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 74:1356-1364, 2009
146. Vartanian JG, Pontes E, Agra IM, et al: Distribution of metastatic lymph nodes in oropharyngeal carcinoma and its implications for the elective treatment of the neck. *Arch Otolaryngol Head Neck Surg* 129:729-732, 2003
147. Plonowska KA, Strohl MP, Wang SJ, et al: Human papillomavirus-associated oropharyngeal cancer: Patterns of nodal disease. *Otolaryngol Head Neck Surg* 160:502-509, 2019
148. Amsbaugh MJ, Yusuf M, Cash E, et al: Distribution of cervical lymph node metastases from squamous cell carcinoma of the oropharynx in the era of risk stratification using human papillomavirus and smoking status. *Int J Radiat Oncol Biol Phys* 96:349-353, 2016
149. Cannon RB, Houlton JJ, Patel S, et al: Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS). *Oral Oncol* 86:296-300, 2018
150. Stanford-Moore GB, Ochoa E, Larson A, et al: Patterns of nodal metastases and predictors of occult disease in HPV-associated oropharynx cancer. *Otolaryngol Head Neck Surg* 164:624-630, 2021
151. Dziegielewski PT, O'Connell DA, Szudek J, et al: Neck metastases in oropharyngeal cancer: Necessity and extent of bilateral treatment. *Head Neck* 35:1461-1467, 2013
152. Zenga J, Jackson RS, Graboyes EM, et al: Oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma. *Laryngoscope* 127:623-630, 2017
153. Kato MG, Ellis MA, Nguyen SA, et al: Predictors of contralateral-bilateral nodal disease in oropharyngeal cancer: A National Cancer Data Base study. *Head Neck* 40:338-348, 2018
154. Sahoavaler A, Lee JJW, Xu W, et al: Contralateral nodal failures in oropharyngeal cancers after TORS and unilateral neck management: A retrospective study. *J Otolaryngol Head Neck Surg* 50:71, 2021
155. Tritter AG, Mehta V, Samuelson M, et al: Incidence of contralateral-bilateral nodes in the human papillomavirus era. *Laryngoscope* 127:1328-1333, 2017
156. Ferris RL, Flamand Y, Weinstein GS, et al: Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). *J Clin Oncol* 38, 2020 (suppl 15; abstr 6500)
157. Sinha P, Lewis JS Jr, Piccirillo JF, et al: Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. *Cancer* 118:3519-3530, 2012
158. Routman DM, Funk RK, Tangsiwong K, et al: Relapse rates with surgery alone in human papillomavirus-related intermediate- and high-risk group oropharynx squamous cell cancer: A multi-institutional review. *Int J Radiat Oncol Biol Phys* 99:938-946, 2017
159. Gillison ML, Trotti AM, Harris J, et al: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. *Lancet* 393:40-50, 2019
160. Mehanna H, Robinson M, Hartley A, et al: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. *Lancet* 393:51-60, 2019
161. Rischin D, King M, Kenny L, et al: Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)—A Trans-Tasman Radiation Oncology Group study. *Int J Radiat Oncol Biol Phys* 111:876-886, 2021
162. Sun L, Shimunov D, Tan EX, et al: Survival and toxicity in patients with human papilloma virus-associated oropharyngeal squamous cell cancer receiving trimodality therapy including transoral robotic surgery. *Head Neck* 43:3053-3061, 2021
163. Nichols AC, Theurer J, Prisman E, et al: Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. *Lancet Oncol* 20:1349-1359, 2019
164. Sanford NN, Hwang WL, Pike LR, et al: Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC. *Oral Oncol* 98:28-34, 2019
165. Gallitto M, Sindhu K, Wasserman I, et al: Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit? *Head Neck* 41:3009-3022, 2019
166. Chen WY, Chen TC, Lai SF, et al: Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. *PLoS One* 14:e0225962, 2019
167. Kelly JR, Park HS, An Y, et al: Comparison of survival outcomes among human papillomavirus-negative cT1-2 N1-2b patients with oropharyngeal squamous cell cancer treated with upfront surgery vs definitive chemoradiation therapy: An observational study. *JAMA Oncol* 3:1107-1111, 2017
168. Haddad R, O'Neill A, Rabinowitz G, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. *Lancet Oncol* 14:257-264, 2013
169. Ghi MG, Paccagnella A, Ferrari D, et al: Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. *Ann Oncol* 28:2206-2212, 2017
170. Cohen EE, Karrison TG, Kocherginsky M, et al: Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. *J Clin Oncol* 32:2735-2743, 2014
171. Hitt R, Grau JJ, López-Pousa A, et al: A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Ann Oncol* 25:216-225, 2014
172. Geoffrois L, Martin L, De Raucourt D, et al: Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 phase III randomized trial. *J Clin Oncol* 36:3077-3083, 2018
173. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. *Lancet* 355:949-955, 2000
174. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 92:4-14, 2009
175. Blanchard P, Bourhis J, Lacas B, et al: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. *J Clin Oncol* 31:2854-2860, 2013
176. Paccagnella A, Ghi MG, Loriggian L, et al: Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. *Ann Oncol* 21:1515-1522, 2010
177. Misiukiewicz K, Gupta V, Miles BA, et al: Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. *Oral Oncol* 95:170-177, 2019
178. Marur S, Li S, Cmelak AJ, et al: E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. *J Clin Oncol* 35:490-497, 2017
179. Siegel RS, Rafei H, Joshi A, et al: Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach. *J Clin Oncol* 36, 2018 (suppl 15; abstr 6004)
180. Sadeghi N, Mascarella MA, Khalife S, et al: Neoadjuvant chemotherapy followed by surgery for HPV-associated locoregionally advanced oropharynx cancer. *Head Neck* 42:2145-2154, 2020
181. Sadeghi N, Khalife S, Mascarella MA, et al: Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. *Head Neck* 42:417-425, 2020
182. Rosenberg A, Agrawal N, Pearson AT, et al: Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial. *J Clin Oncol* 39, 2021 (suppl 15; abstr 6011)
183. Warner L, Chudasama J, Kelly CG, et al: Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. *Cochrane Database Syst Rev* 2014:CD002027, 2014
184. Aaltonen LM, Rautiainen N, Sellman J, et al: Voice quality after treatment of early vocal cord cancer: A randomized trial comparing laser surgery with radiation therapy. *Int J Radiat Oncol Biol Phys* 90:255-260, 2014
185. Carvalho GB, Kohler HF, Lira RB, et al: Survival results of 3786 patients with stage I or II laryngeal squamous cell carcinoma: A study based on a propensity score. *Braz J Otorhinolaryngol* 88:337-344, 2022
186. de Carvalho GB, Kohler HF, de Mello JBH, et al: Organ preservation and oncological outcomes in early laryngeal cancer: A propensity score-based study. *Acta Otorhinolaryngol Ital* 41:317-326, 2021
187. Guimaraes AV, Dedivitis RA, Matos LL, et al: Comparison between transoral laser surgery and radiotherapy in the treatment of early glottic cancer: A systematic review and meta-analysis. *Sci Rep* 8:11900, 2018
188. Hendriksma M, Heijnen BJ, Sjogren EV: Oncologic and functional outcomes of patients treated with transoral CO2 laser microsurgery or radiotherapy for T2 glottic carcinoma: A systematic review of the literature. *Curr Opin Otolaryngol Head Neck Surg* 26:84-93, 2018

189. Sava HW, Dedivitis RA, Gameiro GR, et al: Morphological evaluation of thyroid cartilage invasion in early glottic tumors involving the anterior commissure. *ORL J Otorhinolaryngol Relat Spec* 80: 259-270, 2018
190. Gioacchini FM, Tulli M, Kaleci S, et al: Therapeutic modalities and oncologic outcomes in the treatment of T1b glottic squamous cell carcinoma: A systematic review. *Eur Arch Otorhinolaryngol* 274:4091-4102, 2017
191. Jacobi C, Freundorfer R, Reiter M: Transoral laser microsurgery in early glottic cancer involving the anterior commissure. *Eur Arch Otorhinolaryngol* 276:837-845, 2019
192. Wu Y, Deng Q, Yi X, et al: Effect of transoral laser microsurgery vs open partial laryngectomy on the prognosis of patients with early laryngeal carcinoma: Propensity score-based analysis. *Eur Arch Otorhinolaryngol* 280:1301-1310, 2023
193. Hans S, Baudouin R, Ciriuc MP, et al: Laryngeal cancer surgery: History and current indications of transoral laser microsurgery and transoral robotic surgery. *J Clin Med* 11:5769, 2022
194. Naudo P, Laccourreye O, Weinstein G, et al: Functional outcome and prognosis factors after supracricoid partial laryngectomy with cricohyoidoepexy. *Ann Otol Rhinol Laryngol* 106:291-296, 1997
195. Rizzotto G, Crosetti E, Lucioni M, et al: Oncologic outcomes of supratracheal laryngectomy: Critical analysis. *Head Neck* 37:1417-1424, 2015
196. Vilaseca I, Xavier Aviles-Jurado F, Leher E, et al: C02-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy. *Oral Oncol* 134:106088, 2022
197. Ambrosch P: The role of laser microsurgery in the treatment of laryngeal cancer. *Curr Opin Otolaryngol Head Neck Surg* 15:82-88, 2007
198. Crosetti E, Caracciolo A, Molteni G, et al: Unravelling the risk factors that underlie laryngeal surgery in elderly. *Acta Otorhinolaryngol Ital* 36:185-193, 2016
199. Peretti G, Piazza C, Mora F, et al: Reasonable limits for transoral laser microsurgery in laryngeal cancer. *Curr Opin Otolaryngol Head Neck Surg* 24:135-139, 2016
200. Paderno A, Lancini D, Bosio P, et al: Transoral laser microsurgery for glottic cancer in patients over 75 years old. *Laryngoscope* 132:135-141, 2022
201. Rodrigo JP, Garcia-Velasco F, Ambrosch P, et al: Transoral laser microsurgery for glottic cancer in the elderly: Efficacy and safety. *Head Neck* 41:1816-1823, 2019
202. Jones H, Ross E, Jose J: TLM outcomes in elderly patients with glottic pre-malignancy and early malignancy: A 12-year retrospective study. *Ann Otol Rhinol Laryngol* 130:1392-1399, 2021
203. Vilaseca I, Xavier Aviles-Jurado F, Leher E, et al: C02-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy. *Oral Oncol* 134:106088, 2022
204. Chiesa Estomba CM, Betances Reinoso FA, Lorenzo Lorenzo AI, et al: Functional outcomes of supraglottic squamous cell carcinoma treated by transoral laser microsurgery compared with horizontal supraglottic laryngectomy in patients younger and older than 65 years. *Acta Otorhinolaryngol Ital* 36:450-458, 2016
205. Joo YH, Sun DI, Cho JH, et al: Factors that predict postoperative pulmonary complications after supracricoid partial laryngectomy. *Arch Otolaryngol Head Neck Surg* 135:1154-1157, 2009
206. Department of Veterans Affairs Laryngeal Cancer Study Group; Wolf GT, Fisher SG, et al: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. *N Engl J Med* 324:1685-1690, 1991
207. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 349:2091-2098, 2003
208. Hoffman HT, Porter K, Karnell LH, et al: Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. *Laryngoscope* 116:1-13, 2006
209. Carvalho AL, Nishimoto IN, Califano JA, et al: Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. *Int J Cancer* 114: 806-816, 2005
210. Hinni ML, Salassa JR, Grant DG, et al: Transoral laser microsurgery for advanced laryngeal cancer. *Arch Otolaryngol Head Neck Surg* 133:1198-1204, 2007
211. Laccourreye O, Brasnu D, Biacabe B, et al: Neo-adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidoepexy for advanced endolaryngeal carcinoma classified as T3-T4: 5-year oncologic results. *Head Neck* 20:595-599, 1998
212. Levine PA, Brasnu DF, Ruparel A, et al: Management of advanced-stage laryngeal cancer. *Otolaryngol Clin North Am* 30:101-112, 1997
213. Lima RA, Freitas EQ, Kligerman J, et al: Near-total laryngectomy for treatment of advanced laryngeal cancer. *Am J Surg* 174:490-491, 1997
214. Dias FL, Lima RA, Kligerman J, et al: Therapeutic options in advanced laryngeal cancer: An overview. *ORL J Otorhinolaryngol Relat Spec* 67:311-318, 2005
215. Lefebvre JL, Coche-Dequeant B, Degardin M, et al: Treatment of laryngeal cancer: The permanent challenge. *Expert Rev Anticancer Ther* 4:913-920, 2004
216. Strome SE, Weinman EC: Advanced larynx cancer. *Curr Treat Options Oncol* 3:11-20, 2002
217. Sherman EJ, Fisher SG, Kraus DH, et al: TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. *Laryngoscope* 122:1043-1050, 2012
218. Lin CC, Fedewa SA, Prickett KK, et al: Comparative effectiveness of surgical and nonsurgical therapy for advanced laryngeal cancer. *Cancer* 122:2845-2856, 2016
219. Fu X, Zhou Q, Zhang X: Efficacy comparison between total laryngectomy and nonsurgical organ-preservation modalities in treatment of advanced stage laryngeal cancer: A meta-analysis. *Medicine (Baltimore)* 95:e3142, 2016
220. Riga M, Chelis L, Danielides V, et al: Systematic review on T3 laryngeal squamous cell carcinoma; still far from a consensus on the optimal organ preserving treatment. *Eur J Surg Oncol* 43:20-31, 2017
221. Tang ZX, Gong JL, Wang YH, et al: Efficacy comparison between primary total laryngectomy and nonsurgical organ-preservation strategies in treatment of advanced stage laryngeal cancer: A meta-analysis. *Medicine (Baltimore)* 97:e10625, 2018
222. Kim BH, Park SJ, Jeong WJ, et al: Comparison of treatment outcomes for T3 glottic squamous cell carcinoma: A meta-analysis. *Clin Exp Otorhinolaryngol* 11:1-8, 2018
223. Garcia-León FJ, Garcia-Estépe R, Romero-Tabares A, et al: Treatment of advanced laryngeal cancer and quality of life. Systematic review. *Acta Otorinolaringol Esp* 68:212-219, 2017
224. Timme DW, Jonnalagadda S, Patel R, et al: Treatment selection for T3/T4a laryngeal cancer: Chemoradiation versus primary surgery. *Ann Otol Rhinol Laryngol* 124:845-851, 2015
225. Szuets M, Kuhnt T, Punke C, et al: Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer. *J Radiat Res* 56:159-168, 2015
226. Al-Mamgani A, Navran A, Walraven I, et al: Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: Is the effort worth? *Eur Arch Otorhinolaryngol* 276:575-583, 2019
227. De Virgilio A, Pellini R, Mercante G, et al: Supracricoid partial laryngectomy for radiorecurrent laryngeal cancer: A systematic review of the literature and meta-analysis. *Eur Arch Otorhinolaryngol* 275:1671-1680, 2018
228. Sanabria A, Shah JP, Medina JE, et al: Incidence of occult lymph node metastasis in primary larynx squamous cell carcinoma, by subsite, T classification and neck level: A systematic review. *Cancers (Basel)* 12:1059, 2020
229. Zhang Y, Xu S, Liu W, et al: Rational choice of neck dissection in clinically N0 patients with supraglottic cancer. *Head Neck* 42:365-373, 2020
230. Ferlito A, Silver CE, Rinaldo A: Selective neck dissection (IIA, IIB): A rational replacement for complete functional neck dissection in patients with N0 supraglottic and glottic squamous carcinoma. *Laryngoscope* 118:676-679, 2008
231. Sessions DG, Lenox J, Spector GJ: Supraglottic laryngeal cancer: Analysis of treatment results. *Laryngoscope* 115:1402-1410, 2005
232. Rodrigo JP, Cabanillas R, Franco V, et al: Efficacy of routine bilateral neck dissection in the management of the N0 neck in T1-T2 unilateral supraglottic cancer. *Head Neck* 28:534-539, 2006
233. Jones TM, De M, Foran B, et al: Laryngeal cancer: United Kingdom national multidisciplinary guidelines. *J Laryngol Otol* 130:S75-S82, 2016
234. Ding W, Liu T, Liang J, et al: Supraglottic squamous cell carcinomas have distinctive clinical features and prognosis based on subregion. *PLoS One* 12:e0188322, 2017
235. Mangussi-Gomes J, Danelon-Leonhardt F, Moussalem GF, et al: Thyroid gland invasion in advanced squamous cell carcinoma of the larynx and hypopharynx. *Braz J Otorhinolaryngol* 83:269-275, 2017
236. Mendelson AA, Al-Khatib TA, Julien M, et al: Thyroid gland management in total laryngectomy: meta-analysis and surgical recommendations. *Otolaryngol Head Neck Surg* 140:298-305, 2009
237. Kim JW, Han GS, Byun SS, et al: Management of thyroid gland invasion in laryngopharyngeal cancer. *Auris Nasus Larynx* 35:209-212, 2008
238. Coskun HH, Medina JE, Robbins KT, et al: Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma. *Head Neck* 37:915-926, 2015
239. Medina JE, Ferlito A, Robbins KT, et al: Central compartment dissection in laryngeal cancer. *Head Neck* 33:746-752, 2011
240. Candela FC, Kothari K, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. *Head Neck* 12:197-203, 1990
241. de Bree R, Leemans CR, Silver CE, et al: Paratracheal lymph node dissection in cancer of the larynx, hypopharynx, and cervical esophagus: The need for guidelines. *Head Neck* 33:912-916, 2011
242. Weber RS, Marvel J, Smith P, et al: Paratracheal lymph node dissection for carcinoma of the larynx, hypopharynx, and cervical esophagus. *Otolaryngol Head Neck Surg* 108:11-17, 1993
243. Plaat RE, de Bree R, Kuik DJ, et al: Prognostic importance of paratracheal lymph node metastases. *Laryngoscope* 115:894-898, 2005
244. Timon CV, Toner M, Conlon BJ: Paratracheal lymph node involvement in advanced cancer of the larynx, hypopharynx, and cervical esophagus. *Laryngoscope* 113:1595-1599, 2003
245. Basheeth N, O'Cathain E, O'Leary G, et al: Hypocalcemia after total laryngectomy: Incidence and risk factors. *Laryngoscope* 124:1128-1133, 2014
246. Farlow JL, Birkeland AC, Rosko AJ, et al: Elective paratracheal lymph node dissection in salvage laryngectomy. *Ann Surg Oncol* 26:2542-2548, 2019
247. Lo Galbo AM, de Bree R, Kuik DJ, et al: Paratracheal lymph node dissection does not negatively affect thyroid dysfunction in patients undergoing laryngectomy. *Eur Arch Otorhinolaryngol* 267: 807-810, 2010
248. Elliott MS, Odell EW, Tysome JR, et al: Role of thyroidectomy in advanced laryngeal and pharyngolaryngeal carcinoma. *Otolaryngol Head Neck Surg* 142:851-855, 2010
249. Hall SF, Groome PA, Irish J, et al: The natural history of patients with squamous cell carcinoma of the hypopharynx. *Laryngoscope* 118:1362-1371, 2008
250. Sewnaik A, Hoorweg JJ, Kneigt PP, et al: Treatment of hypopharyngeal carcinoma: Analysis of nationwide study in The Netherlands over a 10-year period. *Clin Otolaryngol* 30:52-57, 2005
251. Lefebvre JL, Chevalier D, Lubinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. *J Natl Cancer Inst* 88:890-899, 1996

252. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst* 101: 498-506, 2009
253. Nakamura K, Shioyama Y, Kawashima M, et al: Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. *Int J Radiat Oncol Biol Phys* 65: 1045-1050, 2006
254. Sato K, Kubota A, Furukawa M, et al: Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma. *Eur Arch Otorhinolaryngol* 272:2001-2006, 2015
255. Nishimura H, Sasaki R, Yoshida K, et al: Radiotherapy for stage I or II hypopharyngeal carcinoma. *J Radiat Res* 53:892-899, 2012
256. Zumsteg ZS, Kim S, David JM, et al: Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. *Cancer* 123:1555-1565, 2017
257. Noronha V, Joshi A, Patil VM, et al: Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: A phase III randomized noninferiority trial. *J Clin Oncol* 36:1064-1072, 2018
258. Sharma A, Kumar M, Bhaskar S, et al: An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial). *J Clin Oncol* 40:6004, 2022
259. Stokes WA, Jones BL, Bhatia S, et al: A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. *Cancer* 123:600-608, 2017
260. Knab BR, Salama JK, Solanki A, et al: Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. *Ann Oncol* 19:1650-1654, 2008
261. Popovtzer A, Burnstein H, Stemmer S, et al: Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy. *Head Neck* 39:227-233, 2017
262. Worden FP, Moyer J, Lee JS, et al: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. *Laryngoscope* 119: 1510-1517, 2009
263. Bozec A, Poissonnet G, Dassonville O, et al: Current therapeutic strategies for patients with hypopharyngeal carcinoma: Oncologic and functional outcomes. *J Clin Med* 12:1237, 2023
264. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 31:845-852, 2013
265. Bonner J, Giral J, Harari P, et al: Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: A secondary analysis of a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg* 142:842-849, 2016
266. Burtless B, Harrington KJ, Greil R, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. *Lancet* 394:1915-1928, 2019
267. Machiels JP, Rene Leemans C, Golusinski W, et al: Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 31:1462-1475, 2020
268. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 359:1116-1127, 2008
269. Cohen EEW, Bell RB, Bifulco CB, et al: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). *J Immunother Cancer* 7:184, 2019
270. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. *EORTC Early Clinical Trials Group*. *Ann Oncol* 5:533-537, 1994
271. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. *J Clin Oncol* 10:1245-1251, 1992
272. Guardiola E, Peyrade F, Chaigneau L, et al: Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer* 40: 2071-2076, 2004
273. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. *J Clin Oncol* 23:5578-5587, 2005
274. Jacobs C, Lyman G, Velez-Garcia E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 10:257-263, 1992
275. Samlowski WE, Moon J, Kuebler JP, et al: Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group Phase II study. *Cancer Invest* 25:182-188, 2007
276. Guigay J, Auperin A, Fayette J, et al: Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPEXtreme): A multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol* 22:463-475, 2021
277. Steel BJ, Cope MR: A brief history of vascularized free flaps in the oral and maxillofacial region. *J Oral Maxillofac Surg* 73:786.e1-11, 2015
278. Bozec A, Poissonnet G, Chamorey E, et al: Free-flap head and neck reconstruction and quality of life: A 2-year prospective study. *Laryngoscope* 118:874-880, 2008
279. De Virgilio A, Costantino A, Festa BM, et al: Surgical prevention of pharyngocutaneous fistula in salvage total laryngectomy: A systematic review and network meta-analysis. *Eur Arch Otorhinolaryngol* 279:5839-5849, 2022
280. Guimaraes AV, Aires FT, Dedivitis RA, et al: Efficacy of pectoralis major muscle flap for pharyngocutaneous fistula prevention in salvage total laryngectomy: A systematic review. *Head Neck* 38: E2317-E2321, 2016 (suppl 1)
281. Tang CG, Sinclair CF: Voice restoration after total laryngectomy. *Otolaryngol Clin North Am* 48:687-702, 2015
282. Mendez LC, Moraes FY, Poon I, et al: The management of head and neck tumors with high technology radiation therapy. *Expert Rev Anticancer Ther* 16:99-110, 2016
283. Marta GN, Silva V, de Andrade Carvalho H, et al: Intensity-modulated radiation therapy for head and neck cancer: Systematic review and meta-analysis. *Radiother Oncol* 110:9-15, 2014
284. Gupta T, Sinha S, Ghosh-Laskar S, et al: Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: Long-term and mature outcomes of a prospective randomized trial. *Radiat Oncol* 15:218, 2020
285. Amini A, Morgan R, Meyer E, et al: Outcomes between intensity-modulated radiation therapy versus 3D-conformal in early stage glottic cancer. *Head Neck* 43:3393-3403, 2021
286. Sher DJ, Adelstein DJ, Bajaj GK, et al: Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. *Pract Radiat Oncol* 7:246-253, 2017
287. Brouwer CL, Steenbakkers RJ, Bourhis J, et al: CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. *Radiother Oncol* 117:83-90, 2015
288. Jensen K, Friberg J, Hansen CR, et al: The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. *Radiother Oncol* 151:149-151, 2020
289. Merlotti A, Alterio D, Vigna-Taglianti R, et al: Technical guidelines for head and neck cancer IMRT on behalf of the Italian Association of Radiation Oncology—Head and Neck Working Group. *Radiat Oncol* 9:264, 2014
290. Gregoire V, Evans M, Le QT, et al: Delineation of the primary tumour clinical target volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. *Radiother Oncol* 126:3-24, 2018
291. Gregoire V, Grau C, Lapeyre M, et al: Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma. *Oral Oncol* 87:131-137, 2018
292. Amarasena I, Herschtal A, D'Costa I, et al: Outcomes of routine intensity modulated radiation therapy quality assurance in a large head and neck cancer center. *Int J Radiat Oncol Biol Phys* 98: 541-546, 2017
293. Corry J, Ng WT, Moore A, et al: Can radiation therapy quality assurance improve nasopharyngeal cancer outcomes in low- and middle-income countries: Reporting the first phase of a prospective International Atomic Energy Agency Study. *Int J Radiat Oncol Biol Phys* 111:1227-1236, 2021
294. McDowell L, Corry J: Radiation therapy quality assurance in head and neck radiotherapy—Moving forward. *Oral Oncol* 88:180-185, 2019
295. Cmelak AJ, Ferris RL, Chen AM, et al: Treatment de-intensification for HPV-positive oropharynx cancer: What is currently acceptable? *J Clin Oncol* 39:2732-2733, 2021
296. Yom SS, Torres-Saavedra P, Caudell JJ, et al: Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). *J Clin Oncol* 39:956-965, 2021
297. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. *Int J Radiat Oncol Biol Phys* 48:7-16, 2000
298. Huang SH, O'Sullivan B, Su J, et al: Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. *Cancer* 126:3426-3437, 2020
299. Jacinto AA, Batalha Filho ES, Viana Lds, et al: Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. *BMC Cancer* 18:1026, 2018

300. Tobias JS, Monson K, Gupta N, et al: Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. *Lancet Oncol* 11:66-74, 2010
301. Vreugdenhil M, Fong C, Sanghera P, et al: Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. *Oral Oncol* 113:105112, 2021
302. Reference deleted
303. Yamazaki H, Nishiyama K, Tanaka E, et al: Radiotherapy for early glottic carcinoma (T1N0M0): Results of prospective randomized study of radiation fraction size and overall treatment time. *Int J Radiat Oncol Biol Phys* 64:77-82, 2006
304. Chera BS, Amdur RJ, Morris CG, et al: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. *Int J Radiat Oncol Biol Phys* 78:461-466, 2010
305. Moon SH, Cho KH, Chung EJ, et al: A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: Results of a Korean Radiation Oncology Group (KROG-0201) study. *Radiother Oncol* 110:98-103, 2014
306. 263. AR: Standardizing Nomenclatures in Radiation Oncology the Report of AAPM Task Group 263. https://www.aapm.org/pubs/reports/RPT_263.pdf, 2018
307. TG119 A: TG-119 IMRT Commissioning Tests Instructions for Planning, Measurement, and Analysis. https://www.aapm.org/pubs/tg119/TG119_Instructions_102109.pdf. AAPM, Version 10/21/2009
308. Lewis PJ, Court LE, Lievens Y, et al: Structure and processes of existing practice in radiotherapy peer review: A systematic review of the literature. *Clin Oncol (R Coll Radiol)* 33:248-260, 2021
309. Manual W-T: Radiotherapy Risk Profile. World Health Organization (WHO), Geneva, WHO Press, 2008
310. Tjong A, Lao L, MacKean J, et al: Faculty of radiation oncology position paper on the use of image-guided radiation therapy. *J Med Imaging Radiat Oncol* 60:772-780, 2016
311. Rudat V, Hammoud M, Pillay Y, et al: Impact of the frequency of online verifications on the patient set-up accuracy and set-up margins. *Radiat Oncol* 6:101, 2011
312. Gupta T, Narayan CA: Image-guided radiation therapy: Physician's perspectives. *J Med Phys* 37:174-182, 2012
313. Jones D: ICRU Report 50—Prescribing, recording and reporting photon beam therapy. *Med Phys* 21:833-834, 1994
314. ICRU Report 62, Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU 50) – ICRU n.d. <https://www.icru.org/report/prescribing-recording-and-reporting-photon-beam-therapy-report-62/>
315. van Herk M: Errors and margins in radiotherapy. *Semin Radiat Oncol* 14:52-64, 2004
316. Stroom JC, Heijmen BJ: Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. *Radiother Oncol* 64:75-83, 2002
317. Mzenda B, Hosseini-Ashrafi ME, Palmer A, et al: Determination of target volumes in radiotherapy and the implications of technological advances: A literature review. *J Radiother Pract* 8:41-51, 2009
318. Mongioi V, Orlandi E, Palazzi M, et al: Set-up errors analyses in IMRT treatments for nasopharyngeal carcinoma to evaluate time trends, PTV and PRV margins. *Acta Oncol* 50:61-71, 2011
319. Yu Y, Michaud AL, Sreeraman R, et al: Comparison of daily versus nondaily image-guided radiotherapy protocols for patients treated with intensity-modulated radiotherapy for head and neck cancer. *Head Neck* 36:992-997, 2014
320. Baron CA, Awan MJ, Mohamed AS, et al: Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: Quality assurance implications for target volume and organs-at-risk margination using daily CT on- rails imaging. *J Appl Clin Med Phys* 16:5108, 2014
321. Houghton F, Benson RJ, Tudor GS, et al: An assessment of action levels in imaging strategies in head and neck cancer using TomoTherapy. Are our margins adequate in the absence of image guidance? *Clin Oncol (R Coll Radiol)* 21:720-727, 2009
322. Zhong R, Song Y, Yan Y, et al: Analysis of which local set-up errors can be covered by a 5-mm margin for cone beam CT-guided radiotherapy for nasopharyngeal carcinoma. *Br J Radiol* 91:20160849, 2018
323. Lai YL, Yang SN, Liang JA, et al: Impact of body-mass factors on setup displacement in patients with head and neck cancer treated with radiotherapy using daily on-line image guidance. *Radiat Oncol* 9:19, 2014
324. Nabavizadeh N, Elliott DA, Chen Y, et al: Image guided radiation therapy (IGRT) practice patterns and IGRT's impact on workflow and treatment planning: Results from a National Survey of American Society for Radiation Oncology Members. *Int J Radiat Oncol Biol Phys* 94:850-857, 2016
325. Zhao LR, Zhou YB, Li GH, et al: The clinical feasibility and performance of an orthogonal X-ray imaging system for image-guided radiotherapy in nasopharyngeal cancer patients: Comparison with cone-beam CT. *Phys Med* 32:266-271, 2016
326. Ciardo D, Alterio D, Jereczek-Fossa BA, et al: Set-up errors in head and neck cancer patients treated with intensity modulated radiation therapy: Quantitative comparison between three-dimensional cone-beam CT and two-dimensional kilovoltage images. *Phys Med* 31:1015-1021, 2015
327. Divneet M, Quoc-Anh H, Betsy W, et al: Comparison of two thermoplastic immobilization mask systems in daily volumetric image guided radiation therapy for head and neck cancers. *Biomed Phys Eng Express* 4:055007, 2018
328. Fortin A, Bairati I, Albert M, et al: Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. *Int J Radiat Oncol Biol Phys* 52:929-936, 2002
329. Naghavi AO, Echevarria MI, Grass GD, et al: Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. *Cancer* 122:3529-3537, 2016
330. Vikram B, Strong EW, Shah J, et al: Elective postoperative radiation therapy in stages III and IV epidermoid carcinoma of the head and neck. *Am J Surg* 140:580-584, 1980
331. Chen Z, King W, Pearcey R, et al: The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literature. *Radiother Oncol* 87:3-16, 2008
332. Harris JP, Chen MM, Orosco RK, et al: Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. *JAMA Otolaryngol Head Neck Surg* 144:349-359, 2018
333. Barton MB, Keane TJ, Gadalla T, et al: The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. *Radiother Oncol* 23:137-143, 1992
334. Robertson C, Robertson AG, Hendry JH, et al: Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. *Int J Radiat Oncol Biol Phys* 40:319-329, 1998